Poster Session 2 – Wednesday, December 7, 2022: 7:00 am CT
   
  Treatment - Adjuvant Therapy: Adjuvant Therapy - Targeted
P2-01-01 Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine
Bartsch R, Harbeck N, Wrobel D, Zaiss M, Terhaag J, Guth D, Distelrath A, Wuerstlein R, Zahn M-O, Lüftner D, Schwitter M, Balic M, Jackisch C, Müller V, Rinnerthaler G, Schmidt M, Zaman K, Schinköthe T, Resch A, Breitenstein U. Medical University of Vienna, Department of Medicine I, Division of Oncology, Vienna, Austria; Breast Center, Department of Obstetrics and Gynecology, and CCC Munich, LMU University Hospital, Munich, Germany; Sozialstiftung Bamberg Klinikum am Bruderwald, Bamberg, Germany; Oncology Practice, Freiburg, Germany; Rottal/Inn Clinic, Eggenfelden, Germany; Gyneco-oncological practice Dr. Guth, Plauen, Germany; Praxisgemeinschaft Onkologie und Urologie, Wilhelmshaven, Germany; Breast Center, Dept. OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany; MVZ Onkologische Kooperation Harz, Goslar, Germany; Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Berlin, Germany; Kantonsspital Graubünden, Chur, Switzerland; Divison of Oncology, Department of Internal Medicine, Medical University Graz, Austria; Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Department of internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological an Molecular Cancer Research (SCI-LIMCR), Paracelsus Medical University, Salzburg Austria, Cancer Cluster Salzburg, Austria; Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Germany; Breast Center, Lausanne University Hospital CHUV, Lausanne, Switzerland; CANKADO Service GmbH, Kirchheim, Germany; Pierre Fabre Pharma GmbH; Divison of Oncology, Brust-Zentrum Zürich, Switzerland.
P2-01-02 Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and potential eligibility for adjuvant Olaparib
Morganti S, Jin Q, Vincuilla J, Buehler R, Ryan S, Stokes S, Parker T, Mittendorf EA, King T, Weiss A, Partridge AH, Bychkovsky B, Curigliano G, Tayob N, Lin NU, Garber J, Tolaney SM, Lynce F. Dana-Farber Cancer Institute; Harvard Medical School; Broad Institute of MIT and Harvard; Dana-Farber Cancer Institute; Dana-Faber Cancer Institute; Broad Institute of MIT and Harvard; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School; Alliance Foundation Trials; Dana-Farber Cancer Institute, Boston, MA, USA; Comprehensive Breast Health Center, Brigham and Women’s Hospital; Breast Oncology Program, Dana-Farber Brigham Cancer Center Division of Cancer Genetics and Prevention; Dana-Farber Cancer Institute; Harvard Medical School; European Institute of Oncology, IRCCS, University of Milano, Milan, Italy; Medical Oncology, Dana-Farber Cancer Institute; Susan F. Smith Center for Women's Cancers, Dana-Farber Brigham Cancer Center; Harvard Medical School; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;
P2-01-03 Withdrawn
P2-01-04 Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab
Debien V, Agostinetto E, Sirico M, Jacobs F, Molinelli C, Moreau M, Paesmans M, De Giorgi U, Santoro A, Taylor D, Duhoux FP, Botticelli A, Barchiesi G, Lambertini M, de Azambuja E, Piccart M. Institut Jules Bordet, Université Libre de Bruxelles (U.L.B); Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”; Humanitas University, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano; Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Data Center, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Universite catholique de Louvain, CHU UCL Namur—Site Sainte-Elisabeth, Namur, Belgium; Cliniques universitaire Saint-Luc-institut Roi Albert II; Policlinico Umberto I Rome - Italy; Dipartimento di Scienze Radiologiche, Oncologiche e Anatomopatologiche, Università di Roma Sapienza; University of Genova - IRCCS San Martino Hospital, Italy; Academic Trials Promoting Team and Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Institut Jules Bordet – Université Libre de Bruxelles, Brussels, Belgium.
P2-01-05 MBQ-167 chemosensitizes triple-negative breast cancer cells to current chemotherapies and reduces paclitaxel-induced metastasis
Grafals-Ruiz N, Cruz-Collazo AM, Torres-Sánchez A, Dharmawardhane S. UPR, School of Medicine.
P2-01-06 Real-world outcome and cost analysis of the addition of pertuzumab to neoadjuvant therapy in localized HER2 positive breast cancer:  a single center experience
Panet F, Young M, Wong S, Dragomir A, Rose AAN, Panasci L. Department of oncology, McGill University; Segal cancer centre, Jewish General Hospital, Lady Davis institute; Faculty of Medicine, Department of Urology, McGill University; Segal cancer centre, Jewish General Hospital, Lady Davis institute.
P2-01-07 Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial
Zhou H, Wang L, Wang L, Guo Z. The First Affiliated Hospital of Soochow University; The First People's Hospital of Changzhou.
P2-01-08 The efficacy of Anlotinib combined with TEC in neo-adjuvant treatment for triple-negative breast cancer and the value of multi-point core needle biopsy in prediction of pathologic complete remission: A retrospective analysis
Ren K, Hong S, Zhu Z, Wang S, Liu J, Gao H, Wang S. The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China.
   
  Treatment - Adjuvant: Adjuvant Therapy - Other
P2-02-01 Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials
Mittal A, Tamimi F, Molto Valiente C, Di Iorio M, Amir E. Princess Margaret Cancer Centre, Division of Medical Oncology, University of Toronto, Department of Medicine, Toronto, ON, Canada; Princess Margaret Cancer Centre, University of Toronto.
P2-02-02 Phase I trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer
Stanton SE, Wisinski KB, Gwin III WR, Coveler A, Liao JB, Burkard M, Bailey H, Kim K, Havinghurst T, DeShong K, Childs JS, Dimond E, Wojtowicz M, Heckman-Stoddard BM, Cecil D, Disis M. Earle Chiles Research Institute; University of Wisconsin Carbone Cancer Center; UW Medicine Cancer Vaccine Institute; University of Wisconsin; National Cancer Institute, DCP; National Cancer Institute.
P2-02-03 Efficacy and safety of the addition of internal mammary irradiation to standard adjuvant radiation in early-stage breast cancer: A systematic review and meta-analysis
Korzets Y, Levitas D, Grubstein A, Corn BW, Amir E, Goldvaser H. Tel Aviv Sourasky Medical Center; Shaare Zedek Medical Center; Rabin Medical Center, Beilinson Hospital, Davidoff Center; Princess Margaret Cancer Centre, University of Toronto.
P2-02-04 De-escalation of bone-targeted treatment: Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
Beltran-Bless A-A, Clemons M, Fesl C, Hlauschek D, Soelkner L, Pond GR, Vandermeer L, Greil R, Balic M, Bjelic-Radisic V, Singer CF, Steger G, Helfgott R, Egle D, Gampenrieder SP, Kacerovsky-Strobl S, Suppan C, Ritter M, Rinnerthaler G, Pfeiler G, Fohler H, Hilton J, Gnant M. University of Ottawa; Ottawa Hospital; Austrian Breast Cancer and Colorectal Study Group, Vienna, Austria; ABCSG; McMaster University; Ottawa Hospital Research Institute; Department of internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological an Molecular Cancer Research (SCI-LIMCR), Paracelsus Medical University, Salzburg Austria, Cancer Cluster Salzburg, Austria; Divison of Oncology, Department of Internal Medicine, Medical University Graz, Austria; Breast Unit, Helios University Clinic, University Witten/Herdecke, Germany; Department of Gynecology and Obstetrics and Comprehensive Cancer Center, Medical University of Vienna, Austria; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Department of Surgery, Ordensklinikum Linz - Sisters of Charity, Linz, Austria; Breast Cancer Center Tirol, Department of Gynecology, Medical University Innsbruck, Austria; Department of internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological an Molecular Cancer Research (SCI-LIMCR), Paracelsus Medical University, Salzburg Austria, Cancer Cluster Salzburg, Austria; St Francis Hospital; Clinical Division of oncology, Medical University of Graz; Medical University Innsbruck; Medical University of Vienna.
P2-02-05 Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States
Odzer N, Jaber Chehayeb R, Lustberg M, Gross CP, Foldi J. Yale School of Medicine; Yale Cancer Center; University of Pittsburgh Medical Center.
P2-02-06 Adjuvant Denosumab treatment in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials
Mastrantoni L, Garufi G, Di Monte E, Maliziola N, Pasqualoni M, Pontolillo L, Pannunzio S, Chiara Cannizzaro M, Di Bello A, Fabi A, Palazzo A, Bria E, Tortora G, Orlandi A. Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore; Precision Medicine in Breast Cancer, Fondazione Policlinico Universitario A. Gemelli,IRCCS Rome - Italy; Fondazione Policlinico Universitario A. Gemelli IRCCS Rome - Italy; Università Cattolica Sacro Cuore Rome - Italy.
P2-02-07 Patients’ selection of daily timing of oral intake of adjuvant hormonotherapy (HT) and everolimus (EVE) for high risk early breast cancer in the UCBG-UNIRAD phase III trial
Giacchetti S, Hamy A-S, Bachelot T, Lemonnier J, Andre F, Cameron DA, Bliss J, Chabaud S, Hardy-Bessard A-C, Lacroix-Triki M, Canon J-L, Bonnefoi HR, Campone M, Dalenc F, Ballesta A, Lévi F, Laas E. Hôpital Saint Louis; Institut Curie; Centre Léon Bérard; R&D Unicancer; Institut Gustave Roussy, Villejuif, France; The University of Edinburgh, Edinburgh Cancer Research; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London; CARIO HPCA; Gustave Roussy; Grand Hôpital de Charleroi; Institut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U1312, and European Organisation for Research and Treatment of Cancer (EORTC); Institut de Cancérologie de l'Ouest, René Gauducheau, Saint-Herblain, France; Institut Claudius Régaud, Toulouse, France; INSERM; Hôpital Paul-Brousse/CNRS.
   
  Prognostic and Predictive Factors-Biomarkers Predicting Tx Response: Predictive for Endocrine Tx
P2-03-01 Sarcopenia on baseline imaging is associated with toxicity-related discontinuation of endocrine therapy in women with early-stage hormone-positive breast cancer
Saraf A, Tahir I, Hu B, Dietrich A-S, Tonnesen PE, Sharp G, Tillman G, Fintelmann F, Jimenez R. Harvard Radiation Oncology Program; Massachusetts General Hospital.
P2-03-02 Prospective assessment of the decision-making impact of the Breast Cancer Index in the BCI Registry Study
Sanft TB, Wong J, O'Neal B, Siuliukina N, Jankowitz RC, Pegram M, Fox J, Zhang Y, Treuner K, O'Shaughnessy J. Yale School of Medicine; Biotheranostics, A Hologic Company; Abramsom Cancer Center, University of Pennsylvania; Stanford School of Medicine; Rocky Mountain Cancer Center, Boulder, CO, USA; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.
P2-03-03 Neutrophil-to-Lymphocyte Ratio (NLR) as a potential prognostic marker in patients with hormone receptor-positive/HER2-negative advanced-stage breast cancer treated with CDK4/6 inhibitors: A focus on ribociclib
Sharaf B, Qaddoumi A, Tamimi F, Abu-Fares H, Daoud R, Abdel-Razeq H. King Hussien Cancer Center.
P2-03-04 Long-term benefit from adjuvant Tamoxifen in luminal A and luminal B breast cancer patients
Dar H, Johansson A, Nordenskjöld A, Perez-Tenorio G, Yau C, Benz CC, Esserman LJ, Nordenskjöld B, Stål O, Fornander T, Lindström LS. Department of Oncology and Pathology, Karolinska Institutet, Sweden; Institution of Clinical Sciences, Department of Oncology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden; Department of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, Linköping, Sweden; University of California, San Francisco and Buck Institute for Research on Aging, Novato, California; Buck Institute for Research on Aging, Novato, California, and Department of Medicine, University of California San Francisco; University of California, San Francisco; Department of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, Linköping, Sweden; Department of Oncology and Pathology, Karolinska Institutet, Sweden.
P2-03-05 HOXB13/IL17RB-low breast cancers are predicted to respond to PIK3CA inhibitors independent of PIK3CA mutational status
Boyraz B, Kirkpatrick G, Kaluziak ST, Morris R, Kreuzer J, Haas W, Iafrate AJ, Sgroi D. Massachusetts General Hospital.
P2-03-06 Real world treatment of node negative low and intermediate recurrence score breast cancer
Globus O, Levanon K, Nili-Gal Yam E. Sheba Medical Center.
P2-03-07 Multi-parametric algorithm integrating on-treatment Ki67 value and standard clinicopathological variables to predict risk of recurrences for women > 70 years old with early ER+HER2- tumours in POETIC trial
Cheang MCU, Dewan M, Kilburn L, Morani G, Zabaglo L, Sidhu K, Tovey H, Zhu X, Holcombe C, Skene A, Smith I, Robertson J, Ring A, Turner N, Bliss J, Dowsett M. Clinical Trials and Statistics Unit, The Institute of Cancer Research, London; Institute of Cancer Research; Breast Cancer Research, The Institute of Cancer Research; Royal Marsden NHS Foundation Trust; Liverpool University Hospital NHS Foundation Trust; Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, UK; The Royal Marsden NHS Foundation Trust, London; University of Nottingham, Nottingham, UK; University Hospitals of Derby and Burton, Derby, UK; The Royal Marsden NHS Foundation Trust, Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK/ Breast Cancer Research Division – The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust; The Institute of Cancer Research, London; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
P2-03-08 Deconstructing the molecular characteristics of ER+ HER2+ early breast cancer in the POETIC trial using multiplex immunofluorescence and gene expression profiles
Zhu X, Xiao H, López-Knowles E, Bergamino Sirvén MA, Alataki A, Maxwell P, Tovey H, Kilburn L, Holcombe C, Skene A, Smith I, Robertson J, Hoadley KA, Salgado R, Bliss J, Turner N, Salto-Tellez M, Schuster G, Dowsett M, Cheang MCU. Clinical Trials and Statistics Unit, The Institute of Cancer Research, London; Breast Cancer Research, The Institute of Cancer Research, London; School of Medicine, Dentistry and Biomedical Sciences Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast; Liverpool University Hospital NHS Foundation Trust; Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, UK; The Royal Marsden NHS Foundation Trust, London; University of Nottingham, Nottingham, UK; University Hospitals of Derby and Burton, Derby, UK; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; GZA-ZNA-Hospitals, Antwerp, Belgium; Peter Mac Callum Cancer Centre, Melbourne, Australia; The Royal Marsden NHS Foundation Trust; The Institute of Cancer Research, London; The Institute of Cancer Research, London; Queen's University Belfast, Belfast; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
P2-03-09 Withdrawn
P2-03-10 DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer
Nanda S, Shea MJ, Schiff R, Osborne CK, Rimawi MF, Fu X. Baylor College of Medicine, Houston, TX, USA; Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX.
P2-03-11 Differential long-term benefit from adjuvant Tamoxifen therapy in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative premenopausal and postmenopausal breast cancer patients
Johansson A, Dar H, Nordenskjöld A, Perez-Tenorio G, Yau C, Benz CC, Esserman LJ, Van 't Veer L, Nordenskjöld B, Stål O, Fornander T, Lindström LS. Department of Oncology and Pathology, Karolinska Institutet, Sweden; Institution of Clinical Sciences, Department of Oncology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden; Department of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, Linköping, Sweden; University of California, San Francisco and Buck Institute for Research on Aging, Novato, California; Buck Institute for Research on Aging, Novato, California, and Department of Medicine, University of California San Francisco; University of California, San Francisco; The University of California, San Francisco CA, USA; Department of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, Linköping, Sweden; Department of Oncology and Pathology, Karolinska Institutet, Sweden.
P2-03-12 Impact of adjuvant endocrine therapy (ET) omission in ER+ breast cancer (BC) treated with neoadjuvant chemotherapy (NAC)
Choong GM, Boughey JC, Hoskin TL, Day CN, Goetz MP. Mayo Clinic; Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA; Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA; Mayo Clinic, Rochester, MN.
P2-03-13 Breast Cancer Index (BCI) identifies fewer patients with high risk of late recurrence and high likelihood of benefit from extended endocrine therapy with invasive lobular compared to invasive ductal carcinoma
Metzger O, Parimi N, Siuliukina N, Zhang Y, Treuner K, Liefers G-J. Dana-Farber Cancer Institute; Biotheranostics, Inc; Biotheranostics, A Hologic Company; Department of Surgery, Leiden University Medical Center.
P2-03-14 Tumor-agnostic measurement of ctDNA levels in first line ER+, HER2- metastatic breast cancer patients as a ; for survival
Verschoor N, Kraan J, de Weerd V, Van NM, Jager A, Sleijfer S, Martens JWM, Wilting SM. Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
P2-03-15 Retrospective study using database for the effectiveness of medroxyprogesterone acetate in patients with ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study
Utsunomiya K, Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S. Matsuyama Red Cross Hospital; Kumamoto University Hospital; Fukushima Medical University; Nagoya University Graduate School of Medicine, Department of Surgery, Breast Oncology NHO Osaka National Hospital; Osaka International Cancer Institute; Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center; Kitakyushu Municipal Medical Center; Ohotani_S Breast Clinic; Department of Breast Oncology, Niigata Cancer Center Hospital; The Cancer Institute Hospital of JFCR, Tokyo, Japan; National hospital organization Kyushu Cancer Center; Showa University School of Medicine; Hachinohe City Hospital; Aichi Cancer Center; Gunma prefectural cancer center; Kyoto University Graduate School of Medicine; JCHO Kurume General Hospital; Kanagawa Cancer Center, Japan; sagara hospital Hakuaikai social medical corporation; Graduate School of Medicine , Kyoto University; Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research.
P2-03-16 Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series
Clelland E, Rothschild HT, Patterson A, Molina-Vega J, Kaur M, Abel MK, Symmans WF, Chien J, Schwartz CJ, Mukhtar R. University of California, San Francisco.
P2-03-17 Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2+ or HER2- metastatic breast cancer
Hunter N, Peterson LM, Mankoff D, Muzi M, Chen D, Gwin III WR, Vinayak S, Davidson NE, Specht JM, Linden H. Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchison Cancer Center; U Pennsylvania; University of Washington Medical Center; University of Washington; UW Medicine Cancer Vaccine Institute; University of Washington, Fred Hutchison Cancer Center, Seattle, WA, USA.
P2-03-18 Clinical use of Breast Cancer Index for prediction of late breast cancer recurrence and prediction of benefit in extended endocrine therapy: A single institution experience
Chacko R, Godbole MM, Springer K, Ali H, Dabak V. Henry Ford Cancer Institute, Henry Ford Health System.
P2-03-19 The efficacy of neoadjuvant endocrine therapy during the waiting period for surgery in postmenopausal hormone receptor positive breast cancer
Maeda Y, Naruse S, Isono Y, Sato A, Yamada M, Matsumoto A, Ikeda T, Jinno H. Department of Surgery, Teikyo University School of Medicine.
P2-03-20 Clinical profiling and comprehensive analysis of candidate genes related to breast cancer estrogen receptor intratumour heterogeneity
Wang X, Yin Y, Fu Z. JiangSu Province Hospital, China; The First Affiliated Hospital of Nanjing Medical University.
P2-03-21 Chemotherapy is not mandatory in premenopausal, node-positive, HR+HER2- breast cancer patients
Yoo T-K, Lee SB, Lee Y, Hwang Y, Shin E, Lee J, Kim HJ, Chung I-Y, Ko BS, Lee JW, Son BY. Asan Medical Center; Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
P2-03-22 Assessment of the relationship between duration of treatment with hormonal therapy and the detection of ESR1 mutations in hormone-receptor positive, HER2 negative, breast cancer
Ayettey-Anie H, Ahmed KA, Washington I, Yamoah K, Knepper T. National Radiotherapy Oncology and Nuclear Medicine Centre, Korle Bu Teaching Hospital; H. Lee Moffitt Cancer Center.
P2-03-23 Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry
Schmitt WD, Jank P, Hoffmann I, Pfitzner BM, Lenz L, Clegg W, Keil E, Ratzel S, Cogan ES, Blohmer J-U, Wimberger P, Kronenwett R, Horst D, Denkert C. Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Institute of Pathology, Berlin, Germany; Institut für Pathologie, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Germany; Institute of Pathology, Charité – Universitaetsmedizin Berlin, Germany; DRK Kliniken Berlin Westend, Institute of Pathology, Berlin, Germany; Myriad Genetics; Akademisches Lehrkrankenhaus der Charité – Universitätsmedizin Berlin; Charité - Universitätsmedizin Berlin; Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Germany; Myriad International GmbH; Charité - Universitätsmedizin Berlin, Germany; Institut für Pathologie, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Germany.
P2-03-24 Predictors of incomplete ovarian function suppression (OFS) in adolescent and young adult (AYA) women with hormone receptor positive (HR+) breast cancer
Anandan A, Ghosh T, Zhao J, Wisinski KB. University of Wisconsin Hospitals and Clinics Carbone Comprehensive Cancer Center; University of Wisconsin Department of Biostastics and Medical Informatics; University of Wisconsin Carbone Cancer Center.
P2-03-25 Pilot study to evaluate circulating tumor DNA (ctDNA) to PET/CT imaging using 18F-Fluorodeoxyglucose (FDG) and 18F-Fluoroestradiol (FES) PET/CT imaging as biomarkers in patients with metastatic breast cancer
Hunter N, Peterson LM, Muzi M, Konnick EQ, Reichel J, Kinahan P, Specht JM, Yung R, Gwin III WR, Linden H, Tran C. Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchison Cancer Center; University of Washington Medical Center; University of Washington; University of Washington, Fred Hutchinson Cancer Center; UW Medicine Cancer Vaccine Institute; University of Washington, Fred Hutchison Cancer Center, Seattle, WA, USA; University of Washington School of Medicine.
   
  Prognostic and Predictive Factors: Response Predictive Factors - Clinical Testing and Validation
P2-04-01 Immunoexpression of markers related to the HER2 pathway in cases of pure positive her2 breast carcinoma treated with trastuzumab
Franco AFV, Waitzberg AFL, Araujo Neto JT, Pasini FS. Universidade Federal de São Paulo; Faculdade de Medicina, Universidade de São Paulo.
   
  Epidemiology, Risk, and Prevention: Prevention - Behavioral Interventions
P2-05-01 Addressing barriers to adherence and quality of life among women recommended to receive chemoprevention for breast cancer prevention
Jones JT, Whisenant M, Brassil KJ, Warlick HG, Solis E, Kamat S, Maliackal A, Walters A, Ponce D, Gonzalez A, Rios D, Emily R. UT Health Houston; UTHealth Cizik School of Nursing; Pack Health, A Quest Diagnostics Company; The University of Texas Health Science Center at Houston; The University of Texas Health Science Center at Houston, Cizik School of Nursing, Department of Research; UT Health; MD Anderson Cancer Center; The University of Texas Health Science Center at Houston, Cizik School of Nursing, Department of Research; UT Health Cizik school of Nursing; UT Health Houston; The University of Texas Health Science Center at Houston Cizik School of Nursing.
P2-05-02 Potential empowerment and risk of genetic counseling with genetic breast cancer risk assessment in personalized Health care : prospective cohort study using genetic counseling outcome scale (GCOS-24)
Kawaguchi-Sakita N, Senda N, Inagaki-Kawata Y, Murakami H, Honda S, Yamada T, Kataoka Y, Takahara S, Tsuyuki S, Yamagami K, Moriguchi Y, Torii M, Kato T, Suwa H, Tsuji W, Suzuki E, Yamauchi A, Okamura R, Kosugi S, Toi M. Kyoto University Hospital; Osaka Red Cross Hospital; Inagaki Breast Surgery Clinic; Kitano Hospital; Shinko Hospital; Kyoto City Hospital; Japanese Red Cross Wakayama Medical Center; Yamato Takada Municipal Hospital; Hyogo Prefectural Amagasaki General Medical Center; Shiga general Hospital; Kobe City Medical Center General Hospital; Yamato Takada Municipal Hospital; Kyoto University; Graduate School of Medicine, Kyoto University, Kyoto, Japan.
P2-05-03 Perceived Guideline Clarity & Deferral to Patient Preferences impact guideline concordant care for breast cancer screening in women age 40-49
Nadler M, Corrado AM, Wilson BE, Desnoyers A, Amir E, Ivers N, Desveaux L. Princess Margaret Cancer Centre, University of Toronto; The Peter Gilgan Centre for Women’s Cancers; Kingston Health Sciences Centre; CHU de Québec, Centre Intégré de Cancérologie; Women's College Hospital; Trillium Health Partner’s Institute for Better Health.
P2-05-04 Safety of breast MRI under general anesthesia
Le-Petross HTC, Bhavsar S, Scoggins ME, Sun J, Bui T, Shin K, Stafford J, Carlson III R, Adrada B. The University of Texas MD Anderson Cancer Center; University of Texas MD Anderson.
   
  Epidemiology, Risk, and Prevention: Prevention - Nutritional Studies
P2-06-01 Improving the health of women on aromatase inhibitors:  A pilot controlled dietary and exercise intervention trial
Carpenter CL, Master AK, Julian O, Ben-Nissan D, Rakoff M, Thames G, Li Z. University of California at Los Angeles; UCLA David Geffen School of Medicine; Breast Cancer Care and Research Fund.
P2-06-02 A randomized controlled trial of soy isoflavone intake on mammographic density among Malaysian women
Rajaram N, Yap B, Eriksson M, Mariapun S, Tan LM, Saat H, Ho E, Mohd Taib NA, Khor GL, Yip CH, Ho Wk, Hall P, Teo SH. Cancer Research Malaysia; Karolinska Institutet; Cancer Research Malaysia/ University of Nottingham Malaysia; University of Malaya Cancer Research Institute; Ramsay Sime Darby Healthcare; University Putra Malaysia; Ramsay Sime Darby Healthcare; University of Nottingham Malaysia; Cancer Research Malaysia.
P2-06-03 Dietary exposure to acrylamide and breast cancer risk: results from the NutriNet-Santé cohort
Bellicha A, Wendeu-Foyet G, Coumoul X, Koual M, Pierre F, Guéraud F, Zelek L, Debras C, Srour B, Sellem L, Kesse-Guyot E, Julia C, Galan P, Hercberg S, Deschasaux-Tanguy M, Touvier M. Sorbonne Paris Nord University, INSERM U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center – University Paris Cité (CRESS), 93017 Bobigny, France; Université Paris Cité, INSERM UMR-S1124, T3S, Toxicologie Environnementale, Cibles thérapeutiques, Signalisation cellulaire et Biomarqueurs, Paris, France; Université Paris Cité, INSERM UMR-S1124, T3S, Toxicologie Environnementale, Cibles thérapeutiques, Signalisation cellulaire et Biomarqueurs, Paris, France. Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, France; Toulouse University, Toxalim (Research Centre in Food Toxicology), INRAE, ENVT, INP-Purpan, UPS, Toulouse, France; Sorbonne Paris Nord University, INSERM U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center – University Paris Cité (CRESS), 93017 Bobigny, France. Oncology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
P2-06-04 Effects of BMI velocity on outcomes in patients with metastatic breast cancer in the Dallas Metastatic Breast Cancer Study
Lim M, Pathak M, Cao M, Moscowitz A, Ladner J, Reddy SM, Chan I. University of Texas Southwestern Medical Center; UT Southwestern.
   
  Epidemiology, Risk, and Prevention: Prevention - Clinical Studies
P2-07-01 Hydroxytyrosol, a component of olive oil for breast cancer prevention in women at high risk
Puri A, Yin Z, Granados-Principal S, Ensor J, Guzman L, Rosato R, Zhao H, Wong S, Patel T, Chang J. Our Lady of Lourdes; Houston Methodist; Fibao; Natera; MD Anderson Cancer Center.
P2-07-02 Effects of different duration of prophylactic antibiotic use on unplanned reoperation in breast cancer patients undergoing implant-based breast reconstruction: A retrospective study with overlap weighting analysis
Li Z, Chen J, Hao S, Cao A-Y, Huang X, Shao Z, Wu J. Fudan University Shanghai Cancer Center; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
   
  Epidemiology, Risk, and Prevention: Prevention - Preclinical Studies and Model Systems
P2-08-01 Licochalcone A from licorice reprograms metabolic and antioxidant pathways in the breast leading to a tumor preventive environment
Hajirahimkhan A, Bartom ET, Chandrasekaran S, Clare S, Khan S. Northwestern University; University of Michigan; Surgery, Breast Surgery Division, Feinberg School of Medicine.
   
  Detection/Diagnosis - Imaging and Screening: Molecular, Functional, and Novel Imaging
P2-09-01 An emerging technology for breast cancer detection - Preliminary data of breast cancer detection using novel low dose positron emission mammography
Freitas V, Waterston ML, Olsen KO, Bubon O, Parker S, Baldassi B, Komarov B, Taeb S, Reznik A. University of Toronto; Radialis Inc.; Radialis Medical; Lakehead University; Thunder Bay Regional Health Research Institute.
P2-09-02 Noninvasive detection of lymph node involvement in subjects with human epidermal growth factor receptor 2 positive (HER2+) breast cancer using the MagSense® HER2 test reagent  – A first-in-human phase 1 study
Jayalakshmi Y, Fox J, Yang N, Zhang M, Proulx R, Reich S. Imagion Biosystems Ltd; Monash Health Moorabbin Hospital; Austin Health.
   
  Detection/Diagnosis - Imaging and Screening: Radiology - Tumor Monitoring
P2-10-01 Correction of gradient non-linearity in multi-site multi-vendor Breast DWI: initial characterization and evaluation of effects on quantitative tumor ADC measures
Liang J, Wilmes LJ, Malyarenko D, Newitt DC, Li W, Gibbs JE, Zimmermann J, the I-SPY 2 Imaging Working Group and the I-SPY 2 Consortium, Chenevert T, Hylton NM. University of California, San Francisco; University of Michigan; Quantum Leap Healthcare Collaborative.
P2-10-02 Impact  of  neoadjuvant  treatment on the accuracy of breast MRI and calliper in premenopausal ER-positive, HER2-negative, and node-positive breast cancer patients: Prospective phase III clinical trial
Gwark S, Ahn SH, Lee JW, Son BH, Ko BS, Kim J, Chung I-Y, Lee SB, Ahn J-H, Jung KH, Kim S-B, Lee HJ, Gong G, Kim HJ. Ewha Womans University Mokdong Hospital; Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Asan Medical Center; Asan Medical Center, University of Ulsan College of Medicine; Asan Medical Center, Seoul, Republic of Korea; University of Ulsan College of Medicine, Asan Medical Center.
   
  Prognostic&Predictive Factors:Prognosis-Biomarkers of Natural History-Prog Factors-Clin Testing&Val
P2-11-01 Secondary endocrine resistance and high Ki-67 labeling index (≥20%) in patients with low genomic risk identified by 21-gene recurrence score
Lee J, Kim H, Bae SJ, Lee JW, Son BH, Ahn SH, Jeong J, Lee SB, Ahn SG. Sacred Heart Hospital, Hallym University, Dongtan; Asan Medical Center; Division of Breast Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
P2-11-02 Biomarkers related to survival benefit in the treatment of metastatic luminal breast cancer (mBC) with cyclin 4/6 inhibitors (CDK 4/6i) plus endocrine therapy (ET)
Morales Murillo S, Gasol Cudós A, Tuset Der-Abrain N, Urdanibia I, Rodriguez Galindo A, Velasco Sánchez A, Vilardell Villellas F, Sánchez Guzmán D, Canosa Morales C, Melé Oliv J, Arbones Cid L. Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain.
P2-11-03 How to make decisions in ductal carcinoma in situ? The first study of clinical applicability of the MSKCC ductal carcinoma in situ nomogram in the prediction of local recurrence risk after breast conserving surgery in a Brazilian cohort
Marques L, Carvalho H, Carvalho F, Rodrigues L, Aguiar F, Barros A. Discipline of Experimental Physiopathology, University of São Paulo Medical School, São Paulo, Brazil; Discipline of Radiotherapy, University of São Paulo Medical School, São Paulo, Brazil; Department of Pathology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil; Discipline of Pathologic Anatomy, University of Pernambuco Medical Sciences School, Recife, Brazil; Discipline of Experimental Physiopathology, University of São Paulo Medical School, São Paulo, Brazil.
P2-11-04 Moved to HER2 Session
P2-11-05 Effects of intrinsic subtypes and 21-gene assay on the early and late recurrence risks in patients with early stage HER2+ breast cancer: An analysis of the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial
Chumsri S, Li Z, Norton N, Moreno-Aspitia A, Colon-Otero G, Knutson KL, Wolff AC, Perez EA, Thompson EA. Mayo Clinic, Jacksonville; Mayo Clinic; Johns Hopkins University, Baltimore, USA.
P2-11-06 Plasma assay of methylated DNA markers (MDM) detects patients with metastatic breast cancer (MBC) compared to healthy controls and treated breast cancer patients with no evidence of disease
Giridhar KV, Couch FJ, Sinnwell JP, Slettedahl SW, Taylor WR, Mahoney DW, Foote PH, O'Connell MC, Robran MJ, Devens ME, Gonser AM, Larson NL, Doering KA, Burger KN, Kaiser M, Allawi H, Ruddy KJ, Olson JE, Kisiel JB. Mayo Clinic; Exact Sciences; Mayo Clinic, Rochester, USA.
P2-11-07 Association of PIK3CA mutations with efficacy in HER2-positive first-line metastatic breast cancer: a meta-analysis
Swain S, Cortés J, Xu B, Lambertini C, Essioux L, Knott A, Restuccia E, Madjar K, De Haas SL. Georgetown University Medical Center, Lombardi Comprehensive Cancer Center and MedStar Health, Washington, DC, USA; International Breast Cancer Center (IBCC), Barcelona, Spain; National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Data & Statistical Sciences, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development Oncology, Roche Products Limited, Welwyn Garden City, UK; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
P2-11-08 Multimodal prediction of breast cancer recurrence assays and risk of recurrence
Howard FM, Dolezal JM, Kochanny S, Hhramtsova G, Vickery J, Srisuwananukorn A, Woodard A, Chen N, Nanda R, Perou C, Olopade OI, Huo D, Pearson A. University of Chicago; University of Chicago, Chicago, IL, USA; University of North Carolina at Chapel Hill; Center for Clinical Cancer Genetics & Global Health, Section of Hematology and Oncology, Department of Medicine, University of Chicago; Department of Public Health Sciences, University of Chicago and Center for Clinical Cancer Genetics & Global Health, Section of Hematology and Oncology, Department of Medicine, University of Chicago.
P2-11-09 Association of 21-gene recurrence score with overall survival in phase 3 TAILORx trial
Yang SX, Yu J, Wang M. Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute; ELIASSEN Group; Department of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health.
P2-11-10 Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial
Bartlett JMS, Xu K, Wong J, Pond GR, Zhang Y, Spears M, Salunga R, Mallon E, Taylor KJ, Hasenburg A, Dirix L, Seynaeve C, J.H. van de Velde C, Rea D, Schnabel CA, Treuner K, Bayani J. University of Edinburgh, Scotland, United Kingdom; Diagnostic Development, Ontario Institute for Cancer Research, Toronto. Ontario, Canada; Biotheranostics, A Hologic Company; McMaster University; Diagnostic Development, Ontario Institute for Cancer Research, Toronto. Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario; Biotheranostics, A Hologic Company; Diagnostics Oncology Research & Development; Department of Pathology, University of Glasgow, Glasgow, United Kingdom; University of Edinburgh Cancer Research Centre, Institute of Genetics and Cancer; University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany; National and Kapodistrian University of Athens, Medical School, Athens, Greece; Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium; Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Department of Surgery, Leiden University Medical Center; Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences. College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Diagnostic Development, Ontario Institute for Cancer Research Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto. Toronto, Ontario, Canada.
P2-11-11 Computer analysis of nuclear morphology with multiple instance learning predicts overall survival for node positive breast cancer patients from SWOG S8814: A blinded validation study
Shao D, Barlow WE, Li H, Lu C, Albain KS, Rae J, Hayes DF, Godwin AK, Thonpson AM, Madabhushi A, Pusztai L. Case Western Reserve University; SWOG Statistics and Data Management Center; Case Western Reserve University,Department of Biomedical Engineering; Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center; University of Michigan Medical School; University of Michigan Comprehensive Cancer Center; University of Kansas Medical Center; Kansas Institute for Precision Medicine; The University of Kansas Cancer Center; Baylor College of Medicine; Case Western Reserve University, Department of Biomedical Engineering/Louis Stokes, Cleveland Veterans Administration Medical Center; Yale University Cancer Center, New Haven, CT, USA.
P2-11-12 Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts
Dieci MV, Bisagni G, Bartolini S, Frassoldati A, Giulio Generali D, Piacentini F, griguolo G, Tagliafico E, Brasó-Maristany F, Chic N, Porra F, Vicini R, D'Amico R, Balduzzi S, Prat A, Conte P, Guarneri V. University of Padova; IRCCS AUSL Reggio Emilia; Ospedale Bellaria di Bologna; Azienda Ospedaliero Universitaria di Ferrara-Arcispedale Sant'Anna; University of Trieste; University of Modena and Reggio Emilia; Department of Surgery, Oncology and Gastroenterology, University of Padua; Division of Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS); Hospital Clínic of Barcelona, Barcelona, Spain ; August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Department of Surgery, Oncology and Gastroenterology, University of Padua; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Breast Cancer Unit, IOB-Quirón Salud, Barcelona, Spain; University of Padua; Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Department of Surgery, Oncology and Gastroenterology, University of Padua.
P2-11-13 High PD-L2 protein expression in cancer cells is an independent marker of unfavorable prognosis in luminal breast tumors
Chaudhary LN, Chervoneva I, Peck AR, Sun Y, Yi M, Langenheim JF, Jorns JM, Kamaraju S, Cheng YC, Burfeind J, Chitambar CR, Hooke JA, Kovatich AJ, Shriver C, Hu H, Palazzo JP, Bibbo M, Hyslop T, Pestell R, Mitchell EP, Rui H. Medical College of Wisconsin; Thomas Jefferson University; Henry JAckson FOundation; Uniformed Services University; Chan Soon-Shiong Institut; Pennsylvania Cancer Center; Medical. College of Wisconsin
P2-11-14 Withdrawn
P2-11-15 Focal ESR1 gene amplification is an independent prognostic marker in postmenopausal patients with endocrine-responsive early breast cancer
Singer CF, Holst F, Steurer S, Burandt E, Lax S, Jakesz R, Rudas M, Stöger H, Greil R, Sauter G, Filipits M, Simon R, Gnant M. Department of Gynecology and Obstetrics and Comprehensive Cancer Center, Medical University of Vienna, Austria; Department of Pathology, University Medical Center Hamburg-Eppendorf; Department of Pathology, Medical University of Graz; Department of Surgery, Medical University Vienna; Department of internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological an Molecular Cancer Research (SCI-LIMCR), Paracelsus Medical University, Salzburg Austria, Cancer Cluster Salzburg, Austria; Department of Pathology, University Medical Center Hamburg-Eppendorf; Center for Cancer Research, Medical University of Vienna, Vienna, Austria; Medical University of Vienna.
P2-11-16 Computerized measurements of nuclear morphology features, mitosis rate, and tubule formation from H&E images predicts disease-free survival in patients with HR+ & LN+ invasive breast cancer from SWOG S8814
Chen Y, Barlow WE, Li H, Lu C, Janowczyk A, Corredor G, Ganesan S, Feldman M, Fu P, Gilmore H, Albain KS, Pusztai L, Rae J, Hayes D, Godwin AK, Thompson AM, Madabhushi A. Shanxi Normal University, School of Computer Science; SWOG Statistics and Data Management Center; Case Western Reserve University, Department of Biomedical Engineering; Case Western Reserve University/Lausanne University Hospital, Precision Oncology Center; Rutgers Cancer Institute of New Jersey; University of Pennsylvania, Perelman School of Medicine; Case Western Reserve University, Department of Population and Quantitative Health Sciences; University Hospitals Cleveland Medical Center; Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center; Yale University Cancer Center, New Haven, CT, USA; University of Michigan Medical School; University of Michigan Comprehensive Cancer Center; University of Kansas Medical Center; Kansas Institute for Precision Medicine; The University of Kansas Cancer Center; Baylor College of Medicine; Case Western Reserve University, Department of Biomedical Engineering/Louis Stokes, Cleveland Veterans Administration Medical Center.
P2-11-17 Prognostic value of Trop2 expression levels in non-metastatic triple-negative breast cancer and correlation with other biomarkers
Jacot W, Chateau M-C, Thezenas S, Guiu S, Firmin N, Boissière-Michot F. Institut du Cancer de Montpellier, Université de Montpellier, INSERM U1194, Paris, France; Montpellier Cancer Institute.
P2-11-18 Serum methylmalonic acid concentrations at breast cancer diagnosis are not associated with distant metastases
Wu Q, Hatse S, García JF, Altea-Manzano P, Billen J, Planque M, Vandekeere A, Lambrechts Y, Richard F, Laenen A, Punie K, Neven P, Nevelsteen I, Floris G, Desmedt C, Gomes A, Fendt S-M, Wildiers H. KU Leuven; Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; VIB-CCB; UZ Leuven; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Belgium; Universitair Ziekenhuis Leuven, Leuven, Belgium; Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; Laboratory for Translation Breast Cancer Research/KU Leuven; MOFFITT Cancer Center.
P2-11-19 Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients
Gianni C, Palleschi M, Scarpi E, Merloni F, Blondeaux E, Puglisi F, Collovà E; Pugliese P, Cognetti F, Giannubilo I, Ruelle T, Bighin C, Del Mastro L, De Giorgi U. Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”; Department of Medical Oncology, IRCCS- Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy; Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST);Dino Amadori, Via P.Maroncelli 40, 47014 Meldola, Italy; IRCCS Ospedale Policlinico San Martino, Genova; Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy; Oncology Unit Cancer Center Department ASST Ovest MIlanese; ASST Lariana, Como; Division of Medical Oncology 1, Regina Elena National Cancer Institute, Rome, Italy; Department of Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy; University of Genova, Genova; University of Genova - IRCCS Ospedale Policlinico San Martino.
P2-11-20 Challenging the current 1-10% cut-off for defining estrogen receptor low positive grade 2-3 estrogen receptor positive, human epidermal growth factor receptor 2 negative early breast cancer
Roobroeck B, Vanderstichele A, Floris G, Desmedt C, Punie K, Han S, Smeets A, Janssen H, Baten A, Weltens C, Nevelsteen I, Baert T, Wildiers H, Neven P. KU Leuven; University Hospitals Leuven; Laboratory for Translation Breast Cancer Research/KU Leuven; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Belgium; Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; UZ Leuven; Universitair Ziekenhuis Leuven, Leuven, Belgium.
P2-11-21 Outcomes and treatment pattern in women with 1 cm or smaller, node-negative hormone receptor-negative breast cancer in Fudan University Shanghai cancer center
Liu X, He M. Fudan University Shanghai Cancer Center.
P2-11-22 Expression of milk whey protein genes in human breast carcinoma cells isolated by LCM impacts prediction of clinical outcomes
Wittliff JL, Daniels MW. University of Louisville.
P2-11-23 Evaluation of T-cell infiltrating lymphocytes vs. Th2 in triple negative breast cancers (TNBC)
Brousse S, Godey F, Laffont E, Tas P, Campillo-Gimenez B, Lavoué V, Le Gallo M. Rennes University Hospital/University of Rennes 1; Centre de lutte contre le cancer Eugène Marquis, Rennes; Inserm UMR_S 1242, Chemistry Oncogenesis Stress Signaling, University of Rennes, Rennes; Department of Pathology, CHU Pontchaillou, Rennes; Service de Gynécologie, CHU de Rennes, Hôpital Sud, Rennes; Oncogenesis, Stress & Signaling Laboratory INSERM UMR1242.
P2-11-24 A novel, rapid and economical prognostic tool for adjuvant therapy decisions in hormone positive breast cancer
Amrania H. Imperial College London.
P2-11-25 A 10-gene signature to predict the prognosis of early-stage triple-negative breast cancer
Kim CM, Park KH, Yu YS, Kim JW, Park JY, Lee JE, Sim SH, Seo BK, Kim JK, Lee ES, Park YH, Kong S-Y. CbsBioscience; Korea University Anam Hospital; Samsung Medical Center; National Cancer Center; Cha University; Samsung Medical Center, Sungkyunkwan University School of Medicine / Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University.
P2-11-26 The prognostic role of circulating tumor DNA after neoadjuvant chemotherapy in triple negative breast cancer with residual tumor
Roseshter T, Klemantovich A, Cavallone L, Aguilar-Mahecha A, Lafleur J, Lan C, Elebute OO, Jenna S, Boileau J-F, Pelmus M, Basik M. Lady Davis Institute; MIMS; Jewish General Hospital Segal Cancer Centre, McGill University, Montréal, Quebec, Canada; Jewish General Hospital.
P2-11-27 Peritumoral desmoplasia in breast cancer – does it matter?
Weydandt L, Wolf B, Horn L-C, Aktas B. Universitätsklinikum Leipzig.
P2-11-28 Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients
Nagahashi M, Toshikawa C, Ling Y, Hayashida T, Kitagawa Y, Futamura M, Kuwayama T, Nakamura S, Yamauchi H, Yamauchi T, Kaneko K, Kanbayashi C, Sato N, Tsuchida J, Moro K, Nakajima M, Shimada Y, Ichikawa H, Lyle S, Miyoshi Y, Takabe K, Okuda S, Wakai T. Hyogo Medical University; Niigata University Graduate School of Medical and Dental Sciences; Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences; Department of Surgery, Keio University School of Medicine; Breast Surgery, Gifu University Hospital; Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine; Showa University School of Medicine; Department of Breast Surgical Oncology, St. Luke's International Hospital; Department of Breast Surgical Oncology, 8Department of Internal Medicine, St. Luke's International Hospital; Department of Breast Oncology, Niigata Cancer Center Hospital; Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences; University of Massachusetts Medical School; Dept of Surgery, Division of Breast and Endocrine Surgery, Hyogo Medical University; Roswell Park Comprehensive Cancer Center; Division of Bioinformatics, Niigata University Graduate School of Medical and Dental Sciences.
P2-11-29 The expression of Claudin-10 in relationship with Her family members in patients with breast cancer
Zhuang X, Jiang WG, Ruge F, Davies E, Xu B, Martin TA. CCMRC, Cardiff University School of Medicine & Xiamen University; Cardiff University; Cardiff University School of Medicine; 3Wales Breast Centre, University Llandough Hospital, Cardiff CF64 2XX, UK; School of Medicine, Xiamen University.
P2-11-30 Performance of tumor vascularity as a biomarker is correlated with the change of tumor vascularity after preoperative systemic treatment in patients with breast cancer
Choi HS, Son EJ, Hany Noh H, In-Jeong Cho I, Lim ST, Lee J-I, Han A. Yonsei University Wonju College of Medicine; Yonsei University College of Medicine.
P2-11-31 Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low  21-gene recurrence scores: A single institutional study with 10-year follow-up
Uras C, Cabıoğlu N, Tokat F, Kara H, Er O, Korkmaz T, Bese N, Ince U. Acibadem University, School of Medicine, Department of Surgery; Istanbul University, Istanbul Faculty of Medicine, Department of Surgery; Acibadem University, School of Medicine.
P2-11-32 Withdrawn
P2-11-33 Striatin and its interactive proteins Protein Phosphatase-2 (PP2) and PP2 regulatory elements in breast cancer
Li AX, Sanders AJ, Martin TA, Ye L, Ruge F, Dou Q, Davies E, Jiang WG. Cardiff University School of Medicine; Cardiff University; 3Wales Breast Centre, University Llandough Hospital, Cardiff CF64 2XX, UK.
P2-11-34 Mitotic spindle hotspot counting using deep learning networks is highly associated with clinical outcomes in patients with early-stage triple-negative breast cancer who did not receive systemic therapy
Leon-Ferre RA, Carter JM, Zahrieh D, Sinnwell JP, Salgado R, Suman V, Hillman D, Boughey JC, Kalari KR, Couch FJ, Ingle JN, Balkenkohl M, Ciompi F, van der Laak J, Goetz MP. Mayo Clinic; University of Alberta, Edmonton, Canada; Ultragenyx; GZA-ZNA-Hospitals, Antwerp, Belgium; Peter Mac Callum Cancer Centre, Melbourne, Australia; Mayo Clinic, Rochester MN; Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA; Radboud University Medical Center.
P2-11-35 A tight junctional scaffold protein MUPP1/MPDZ and its docking proteins, angiomotins in breast cancer
Gao H, Ruge F, Ye L, Lane J, Davies E, Jiang WG, Martin TA. Cardiff University; Cardiff University School of Medicine; Wales Breast Centre, University Llandough Hospital.
P2-11-36 Osteopontin splice variants indicate prognosis in premalignant breast lesions
Weber GF, Ziolkowski P. University of Cincinnati; Wroclaw Medical Universitty.
   
  Treatment: Research Resources - Tissue and Data Banks
P2-12-01 A comprehensive assessment of researcher needs to increase biospecimen donations for breast cancer research: A Patients and Researchers Together (PART) Program
Morris H, Van Lokeren M, Spears PA, Potter JA, Branch V, Patient And Researchers Together Team†, Perou CM, Carey LA. UNC Lineberger Comprehensive Cancer Center; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Alliance for Clinical Trials in Oncology.
P2-12-02 ClinicalomicsDB - Bridging the gap between clinical omics data and machine learning
Moon CI, Jia B, Zhang B. Baylor College of Medicine; Carleton College.
   
  Treatment: Research Resources - Clinical Trials Design and Management
P2-13-01 Enrollment trends among patients with breast central nervous system metastasis in active clinical trials
Elghawy O, Banfield W, Wang J, Horton B, Kaur V. University of Virginia Cancer Center.
P2-13-02 COBRA: Characteristics and Outcomes of patients with BReast cancer in phAse I trials at Gustave Roussy Cancer center
Seknazi L, Geraud A, Goldschmidt V, Baldini C, Champiat S, Massard C, Postel-Vinay S, Marabelle A, Bahleda R, Hollebecque A, Smolenschi C, Gazzah A, Michot J-M, Martin-Romano P, Vozy A, Vuagnat P, Danlos F-X, Bayle A, Mahjoubi L, Pistilli B, Loriot Y, Ponce-Aix S, Ouali K. Gustave Roussy Cancer Center, Villejuif, France; DITEP and Breast Cancer Unit, Gustave Roussy Cancer Center, Villejuif, France; DITEP, Gustave Roussy Cancer Center, Villejuif, France; Gustave Roussy; DITEP, Gustave Roussy Cancer Center, Villejuif, France.
P2-13-03 Feasibility of generating an external control comparator using RWD by matching with previously conducted RCTs:  CDK4/6 Inhibitors for the treatment of metastatic breast cancer
Osgood C, Fan J, Gao X, Keane C, Bryan J, Roose JP, Bloomquist E, Torres A, Baxi S, Nussbaum N, Rivi F, Tang S, Nunes I, Beaver J, Rivera DR, Howie L, Paliwal P, Amiri-Kordestani L. Center for Drug Evaluation and Research, US Food and Drug Administration; Flatiron Health, Inc; Oncology Center of Excellence, US Food and Drug Administration; Food and Drug Administration.
P2-13-04 Inclusion of patients with leptomeningeal disease in phase III randomized clinical trials of patients with advanced breast cancer, lung cancer, and melanoma: A systematic review
Sharma A, Corbett K, Qazi M, Soliman H, Sahgal A, Das S, Lim-Fat MJ, Pond GR, Jerzak K. Michael G. DeGroote School of Medicine; Alberta Health Services; Faculty of Medicine, University of Toronto; Sunnybrook Health Sciences Centre; St Michael's Hospital: Unity Health Toronto; McMaster University.
   
  Treatment - Research Resources: Clinical Trials Design and Management
P2-13-05 Triple Negative Breast Cancer (TNBC) patients are more likely to digitally explore clinical trial options and prior to receiving treatment for advanced disease compared to non-TNBC patients
Safran M, Lapidot Y, Bader T, Gaziel A. Trialjectory.
   
  Treatment - Surgery and Radiotherapy: Surgery
P2-14-01 Molecular fluorescence-guided surgery using BEVA800 for the assessment of tumor margins during breast conserving surgery of patients with primary breast cancer (MARGIN-II)
Kolberg H-C, Röhm C, Stachs A, Schütz F, Blohmer J-U, Wetzig S, Hartmann S, Heil J, Hahn M. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany; Universitätsklinikum Tübingen; Universitätsfrauenklinik Rostock; Diakonissen-Stiftungs-Krankenhaus Speyer; Charité - Universitätsmedizin Berlin; Marienkrankenhaus Schwerte; Department of Gynecology and Obstetrics, Breast Unit, Heidelberg University Hospital, Heidelberg, Germany.
P2-14-02 Surgical options of the breast and clinical outcomes in breast cancer patients after neoadjuvant chemotherapy: a single-center retrospective study
Sang Y, Chen J, Yang B, Hao S, Huang X, Liu G, Shao Z, Su J. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China; Fudan University Shanghai Cancer Center, Shanghai, China.
P2-14-03 Learning curve for Robotic assisted nipple sparing mastectomy:  a single institution experience
Kim YJ, Chung SY, Chae BJ, Yu J, Lee JE, Ryu JM. Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Samsung Medical Center, Sungkyunkwan University School of Medicine; Samsung Medical Center.
P2-14-04 Withdrawn
P2-14-05
Patient rather than tumor factors predict contralateral prophylactic mastectomy for inflammatory breast cancer

Drapalik LM, Amin AL, Simpson A, Rock L, Freyvogel M, Shenk R, Miller ME. University Hospitals / Case Western Reserve University School of Medicine; University Hospitals Cleveland Medical Center; University Hospitals; University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine.
P2-14-06 Prospective, multicenter, clinical validation study of the repeatability and accuracy of internal mammary sentinel lymph node biopsy with modified injection technique (CBCSG026/CBCSG027)
Wang Y-S, Lu Q, Zhu S-G, Zhao W-H, Yang G-L, Huang Y-X, Zhong H, Sun X, Qiu P. Shandong Cancer Hospital & Institute, Jinan, Shandong, China; Sichuan University Huaxi Hospital, Chengdu, Sichuan, China; Department of Breast Surgery, Qindao University Medical College Affiliated Yantai Yuhuangding Hospital; Zhejiang University Sir Run Run Shaw Hospital, Hangzhou Zhejiang, China; Chongqing Medical University First Hospital, Chongqing, China; Harbin Medical University Cancer Hospital, Harbin Helongjiang; The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang , China; Shandong Cancer Hospital & Institute, Jinan, Shandong, China.
P2-14-07 Omission of sentinel lymph node biopsy in patients with early stage breast cancer: Looking beyond the choosing wisely guidelines for age  < 70
Carleton N, Saadawi G, Oesterreich S, Lee AV, Diego E. University of Pittsburgh Medical Center; Realyze Intelligence; University of Pittsburgh; UPMC Hillman Cancer Center; University of Pittsburgh.
P2-14-08 Trends in neoadjuvant systemic therapy rates in Europe: Pre-planned substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Weber WP, Matrai Z, Hayoz S, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Ruhstaller T, Muenst S, Ackerknecht M, Kurzeder C, Küemmel S, Bjelic-Radisic V, Smanykó V, Vrieling C, Satler R, Meyer I, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maráz r, Sarlos D, Dedes KJ, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Sávolt Á; Singer CF, Reitsamer R, Winkler J, Lam Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, Ostapenko V, Fitzal F, Heidinger M, Maggi N, Schulz A, Markellou P, Lelièvre L, Egle D, Heil J, Knauer M, Tausch C. Breast Center, University Hospital of Basel, Basel, Switzerland; Hamad Medical Corporation, General Surgery, Doha, Qatar; SAKK Coordinating Center, Bern, Switzerland; Department of Radiation Oncology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland; Breast Center, St. Gallen Cantonal Hospital, St. Gallen, Switzerland; Department of Radiation Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland; Institute of Radiotherapy, Klinik Hirslanden, Zurich, Switzerland; University Hospital of Basel; Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland; Tumor and Breast Center Eastern Switzerland, St. Gallen, Switzerland; Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland; Department of Biomedicine, University Hospital Basel, Basel, Switzerland; Breast Center, University Hospital of Basel, Basel, Switzerland; Breast Unit, Kliniken Essen-Mitte, Essen, Germany; Breast Unit, Helios University Clinic, University Witten/Herdecke, Germany; Centre of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Radiation Oncology, Hirslanden Clinique des Grangettes, Geneva, Switzerland; Breast Center, Cantonal Hospital Winterthur, Winterthur, Switzerland; Lindenhof Hospital, Praxis Frauenzentrum, Bern, Switzerland; Breast Center, Réseau Hospitalier Neuchâtelois, La Chaux-de-Fonds, Switzerland; Breast Center, Cantonal Hospital Lucerne, Lucerne, Switzerland; Department of Gynecology, Centre Hospitalier du Valais Romand (CHVR), Hôpital de Sion, Switzerland; Breast Center Graubünden, Cantonal Hospital Graubünden, Chur, Switzerland; Breast Center, City Hospital Triemli, Zurich, Switzerland; Department of Oncology, Bacs-Kiskun Country Hospital, Kecskemet, Hungary; Breast Center, Cantonal Hospital Aarau, Aarau, Switzerland; Breast Cancer Center, University Hospital of Zurich, Zurich, Switzerland; Breast Center, Cantonal Hospital Baden, Baden, Switzerland; Breast Center Bern, Lindenhof Group, Bern, Switzerland; Breast Center Zürich, Bethanien & Spital Zollikerberg, Zurich, Switzerland; Department of Gynecology and Obstetrics, City Hospital, Dornbirn, Austria; Department of Gynecology and Obstetrics, Klinikum Wels-Grieskirchen, Wels, Austria; Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary; Department of Gynecology and Obstetrics and Comprehensive Cancer Center, Medical University of Vienna, Austria; Breast Center, Paracelsus Medical University of Salzburg, Salzburg, Austria; Breast Center, Bethesda Hospital Basel, Basel, Switzerland; Breast Center, University Hospital of Geneva, Geneva, Switzerland; Breast Center Thurgau, Münsterlingen, Switzerland; Spital Limmattal, Schlieren, Switzerland; Breast Center GSMN, clinique de Genolier, Genolier, Switzerland; Brustzentrum Freiburg, Centre du sein Fribourg, Fribourg, Switzerland; National Cancer Institute, Vilnius, Lithuania; Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria; Breast Center, University Hospital of Basel, Basel, Switzerland; University Hospital of Basel, Basel, Switzerland; Breast Center, St. Gallen Cantonal Hospital, St. Gallen, Switzerland; Breast center, CHUV, Lausanne, Switzerland; Breast Cancer Center Tirol, Department of Gynecology, Medical University Innsbruck, Austria; Department of Gynecology and Obstetrics, Breast Unit, Heidelberg University Hospital, Heidelberg, Germany; Tumor and Breast Center Eastern Switzerland, St. Gallen, Switzerland; Breast Center Zurich, Zurich, Switzerland.
P2-14-09 Sensory evaluation of nipple-areolar complex after nipple-sparing mastectomy: A comparison of incision approaches
Kook Y, Jang JS, Baek SH, Bae SJ, Ahn SG, Jeong J. Gangnam Severance Hospital; Division of Breast Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
P2-14-10 Axillary reverse mapping aids in reducing the rates of BCRL in underserved ethnically diverse population
Bhimani F, McEvoy M, Johnson K, Feldman S. Montefiore Medical Center.
P2-14-11 Oncological outcomes in patients undergoing targeted axillary dissection with carbon marker
Budel LR, Spautz CC, Louveira MH, Cavalcanti TCS, Fornazari AC, Gasperin Jr, P, Nissen LP, Budel VM. Universidade Federal do Paraná; Centro de Doenças da Mama- Breast Unit Nossa Senhora das Graças Hospital.
P2-14-12 Endoscopic nipple-sparing mastectomy : A single institutional experience of 50 consecutive cases
Lee H, Cho K, Chang Y, Son G. Korea University College of Medicine.
P2-14-13 Propensity score matching for survival outcomes in breast cancer patients with nipple sparing mastectomy versus total mastectomy and breast-conserving surgery: a single-center retrospective study
Xiong M, Hao S, Chen J, Huang X, Liu G, Shao Z, Wu J. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
P2-14-14 Effect Of intra-operative and post-operative topical tranexamic acid on early post-operative complications in patients undergoing axillary lymph node dissection for breast cancer- A randomized controlled study
Pachimatla AG, Irrinki RNNS, Laroiya I, Khare S. Post Graduate Institute of Medical Education and Research; PGIMER Chandigarh.
P2-14-15 Comparison of recurrence-free survival according to axillary surgery extent for clinical N0, sentinel node(s) positive, primary breast cancer patients who underwent total mastectomy
Chun JW, Kim H-K, Lee H-B, Moon H-G, Lee JW, Han W. Seoul National Univ. Hospital, Surgery, Korea; Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
P2-14-16 Breast surgery for metastatic breast cancer: a Cochrane systematic review
Tosello G, Riera R, Christofaro D, Oliveira C, Cruz M, Paulo TR, Mota BS. Instituto do Cancer Oeste Paulista; Hospital Sírio Libanês; Universidade Estadual Paulista (Unesp); Universidade do Oeste Paulista (UNOESTE); Hospital Sírio-Libanês; Universidade Federal do Rio Grande do Norte; Instituto do Cancer do Estado de São Paulo.
P2-14-17 Withdrawn
P2-14-18 Oncological outcomes of nipple-sparing mastectomy after neoadjuvant chemotherapy
Rabinovich I, Nissen LP, Soares IC, Fornazari AC, Spautz CC, Sebastião APM, Urban CA, Anselmi KF, Schunemann E, Kuroda F, Doria MT, Andrade ACS, Lima RS. Universidade Federal do Paraná; Centro de Doenças da Mama- Breast Unit Nossa Senhora das Graças; Centro de Doenças da Mama- Breast Unit Nossa Senhora das Graças Hospital.
P2-14-19 Targeted axillary lymph node dissections using radar reflector localization can reduce unnecessary axillary lymph node
Lunt L, Coogan A, Madrigrano A, O'Donoghue C. Rush University Medical Center.
P2-14-20 Comparison of robot-assisted nipple sparing mastectomy with conventional nipple sparing mastectomy: a single-center experience
Young You J, Lee H, Lee E-S, Jung SP. Korea University Anam Hospital.
P2-14-21 NiToNo Study. Evaluation in terms of quality of life and upper extremity functionality after targeted axillary dissection versus lymphadenectomy
Vila Homs L, Carrillo-Guivernau ML, Sampol C, Matheu Capo G, Camarasa P, Serra C, Mariño M, Tarongí A, Cordoba O, Perelló A. Hospital Universitari Son Espases; Hospital son Espases; Hospital Son Espases, Palma, Illes Balears, Spain.
P2-14-22 Evaluation of male breast cancer and the application of sentinel lymph node biopsy: A multi-center retrospective study
Shang Q, Wei Y, Qiao G, Li J, Wang X. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Anyang Cancer Hospital; The Affiliated Yantai Yuhuangding Hospital of Qingdao University; The First Affiliated Hospital of Zhengzhou University.
   
  Treatment - Surgery and Radiotherapy: Reconstruction
P2-15-01 Withdrawn
P2-15-02 Omentum-lipoaspirate free-flap breast reconstruction in women with BMI  < 25
Wapnir IL, Dua MM, Zak Y, Nguyen D. Stanford Cancer Institute/Stanford University; Stanford.
P2-15-03 Impact of radiotherapy on the long-term patient-reported outcomes of immediate breast reconstruction: The UK Brighter
Johnson L, White P, Jeevan R, Browne J, Gulliver-Clarke C, O'Donoghue J, Mohiuddin S, Hollingworth W, Fairbrother P, MacKenzie M, Holcombe C, Potter S. Bristol Medical School; University of West of England; Manchester University NHS Foundation Trust; University College Cork; Western Sussex Hospitals NHS Foundation Trust; Newcastle on Tyne Hospitals NHS Foundation Trust; University of Bristol; Independent Cancer Patients’ Voice (ICPV); Liverpool University Hospital NHS Foundation Trust.
P2-15-04 Surgical outcomes of ambulatory mastectomy with immediate alloplastic reconstruction for breast cancer or risk reduction
Sandhu S, Cil TD, Escallon JM, Brown M, Semple J, Lim D. Women's College Hospital; University Health Network / University of Toronto; University of Toronto; Women's College Hospital.
P2-15-05 Prepectoral versus subpectoral implant-based breast reconstruction: A systemic review and meta-analysis
Ostapenko E, Nixdorf L, Devyatko Y, Wimmer K, Exner R, Fitzal F. Department of General Surgery and Breast Health Center, Medical University of Vienna, Vienna, Austria; Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Medical University of Vienna; Vienna General Hospital (Medical University of Vienna); Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria; Vienna General Hospital.
P2-15-06 Light-based bioprinting of vascularized fatty tissue for the development of biological breast implants
Hedemann N, Thomas A, Tribian N, Kloke L, Bauerschlag D, van Mackelenbergh M. Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Cellbricks GmbH.
P2-15-07 Current status of latissimus dorsi flaps with or without implants for breast reconstruction in patients with breast tumor: A single-center retrospective study
Zheng S, Chen J, Hao S, Yang B, Huang X, Liu G, Wu J. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Fudan University, Shanghai Medical College, Shanghai, China; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China; Fudan University Shanghai Cancer Center, Shanghai, China; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032 China Department of Oncology, Fudan University Shanghai Medical College, Shanghai, 200032 China.
P2-15-08 Aesthetic incisions and early complications  for nipple-sparing mastectomy followed by immediate breast reconstruction
Pimentel Cavalcante F, Novita G, Oliveira Lima T, Alcantara R, Cardoso A, Ulisses F, Zerwes F, Millen E. Hospital Geral Fortaleza (HGF); Hospital Albert Einstein; PUC-RS; Oncoclinicas.
P2-15-09 Impact of neoadjuvant chemotherapy on the short- and long-term outcomes in patients who underwent immediate breast reconstruction after mastectomy
Nogi H, Ogiya A, Kondo N, Ishitobi M, Yamauchi C, Mori H, Shimo A, Narui K, Nagura N, Seki H, Sasada S, Sakurai T, Shien T. The Jikei University School of Medicine; The Cancer Institute Hospital Of JFCR; Nagoya City University Graduate School of Medical Sciences; Mie University Hospital; Shiga General Hospital; Tokyo Medical and Dental University; St. Marianna University School of Medicine; Yokohama City University Medical Center; St Luke's International Hospital; Saitama Medical Center; Hiroshima University; Sakurai Breast Clinic; Okayama university Hospital.
P2-15-10 Impact of the withdrawal of textured breast implants from the market on breast reconstruction practices
Jankowski C, Martinez M, Laura V, Burnier P, Coutant C. Centre Georges-François Leclerc, Dijon, FRANCE.
   
  Tumor Cell and Molecular Biology: Cellular Mechanisms
P2-16-01 The Kinesin-like protein Kif11 is essential for the Survival of TP53-mutant triple negative breast cancer cells
Lanier A, Mazumdar A, Tahaney W, Brown P. MD Anderson Cancer Center, Department of Clinical Cancer Prevention; Monte Rosa Therapeutics.
P2-16-02 TXNIP-dependent tumor suppressive pathways in breast cancer growth and progression
Singh J, Sah B, Liu L. Hormel Institute University of Minnesota.
P2-16-03 The Speckle-type POZ protein (SPOP) inhibits breast cancer malignancy by destabilizing oncogene TWIST1
Wei C, Liu Y, Liu X, Cheng J, Fu J, Xiao X, Moses RE, Li X, Fu J. Southwest Medical University; East China Normal University; Southwest Medical University; Baylor College of Medicine; Research Center for Preclinical Medicine, Southwest Medical University.
P2-16-04 MNX1 promotes tumor sensitivity to HER2-targeted therapy in HER2-positive breast cancer
Chi W-R, Xiu B, Xiong M, Li p, Zhang Q, Li L, Hou J, Zhou X, Sang Y, Chen M, Zhang L, Xue J, Chi Y, Wu J. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China; Department of Breast Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200032 China; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032 China Department of Oncology, Fudan University Shanghai Medical College, Shanghai, 200032 China.
P2-16-05 Targeting EZH2 to overcome chemoresistance in triple negative breast cancers employing combinatorial approach
Shankar E, SNC S, Rima XY, Kushwaha P, Verma S, Sarathy GK, Kulkarni A, Allimuthu D, Reátegui E, Gupta S, Ramaswamy B. Ohio State University; Indian Institute of Technology Kanpur; Case Western Reserve University; Ohio State University Comprehensive Cancer Center.
P2-16-06 Protein expression and subcellular localization of a clathrin adaptor AP-1 associate with tumor growth activity in breast cancer
Hoshi N, Tachibana K, Uemura T, Nishimagi Y, Noda M, Okano M, Abe S, Otake T, Waguri S. Fukushima Medical University, Department of Breast Surgery; Fukushima Medical University, Department of Anatomy and Histology; Kita Fukushima Medical Center.
P2-16-07 Overexpression of the alpha subunit of the epithelial sodium channel in MDAMB231 breast cancer cells reduces cell migration and proliferation
McQueen S, Ware A, Cunliffe H, McDonald F. Department of Physiology, School of Biomedical Sciences, University of Otago.
P2-16-08 Withdrawn
P2-16-09 Dual Specific Phosphatase-7 (DUSP7/PYST2) and its role in regulating vascular endothelial functions
Ji W, Jiang WG, Ye L, Martin TA. Cardiff University.
   
  Tumor Cell and Molecular Biology: DNA Damage and Repair
P2-17-01 Targeted CRISPR screen to identify synthetic lethal combinations between APOBEC3B and DNA repair
Stefanovska B, Lin K, Troness B, Myers C, Harris R. Howard Hughes Medical Institute, University of Texas Health San Antonio; Department of Computer Science and Engineering, University of Minnesota; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio; Howard Hughes Medical Institute, University of Texas Health San Antonio, Department of Biochemistry and Structural Biology, University of Texas Health San Antonio.
P2-17-02 SMC6 down-regulation: marker of genetic instability and poor outcome in breast cancer
Rotea Mangone FR, Krepischi ACV, Carraro DM, Nagai MA. Center for Translational Research in Oncology, Cancer Institute of the State of São Paulo (ICESP), São Paulo, Brazil; Department of Genetics and Evolutionary Biology/Human Genome and Stem Cell Research Center, Institute of Biosciences, University of São Paulo, São Paulo, Brazil; Genomics and Molecular Biology Group, CIPE/Genomic Diagnostic Center - A. C. Camargo Cancer Center, São Paulo, Brazil; Cancer Institute of the State of São Paulo, Center for Translational Research in Oncology, Discipline of Oncology, Department of Radiology and Oncology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
P2-17-03 Preclinical study of trastuzumab deruxtecan (T-Dxd; DS-8201a) in combination with DNA damage response pathway inhibitors in HER2-low/Hormone receptor negative breast cancer patient-derived xenograft models
Gonzalez-Gonzalez A, Guo Z, Meroni A, Cybulla E, Hoog J, Vindigni A, Ma CX. Washington University in St. Louis School of Medicine; Washington University School of Medicine.
P2-17-04 Pharmacological inhibition of LY6K induced cell cycle arrest and DNA damage by disrupting the LY6K-Histone-Aurora B signaling axis
Selvanesan B, Varghese S, Andrys J, Arriaza R, Prakash R, Tiwari P, Olsen C, Huplo D, Gusev Y, Patel M, Contente S, Sanda M, Wilkerson M, Dalgard C, Shimizu LS, Chruszcz M, Borowski T, Upadhyay G. Uniformed Services University of Health Sciences; Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences; University of South Carolina; Georgetown U; USU; Georgetown; Max Planck; USC.
   
  Tumor Cell and Molecular Biology: Epigenetics
P2-18-01 Matched single-cell RNA-seq and single-cell ATAC-seq of male breast cancers nominate salient cancer-specific enhancers
Wisniewska K, Kim H, Regner MJ, Spanheimer P, Franco HL. University of North Carolina, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
P2-18-02 Promoter hypomethylation associated upregulation of MEN1 mRNA expression and its correlation with pathological parameters in Indian breast cancer patients
Massey S, Khan A, Khan A, Deo SVS, Akhtar S. Jamia Millia Islamia, New Delhi; UT Health San Antonio MD Anderson Cancer Center; All India Institute of Medical Science, New Delhi.
   
  Tumor Cell and Molecular Biology: Hormonal Factors and Receptors
P2-19-01 Characterization of fully human internalizing anti-HER2 monoclonal antibodies that compete with Trastuzumab for binding to HER2
Serrero G, Dong J, Yue B, Yerramalla U, Hayashi J. A&G Pharmaceutical Inc; Precision Antibody.
P2-19-02 Androgen mediated signaling induces epithelial to mesenchymal transition phenotype in MDA-MB-453 breast cancer cells and human breast tumors
Rajarajan S, Snijesh VP, Nair MG, Apoorva D, Chandrakala M, Nimbalkar VP, Pillai M, Jolly MK, Prabhu JS. St.John's Research Institute, Bangalore; Indian Institute of Science.
   
  Tumor Cell and Molecular Biology: Immunology and Preclinical Immunotherapy
P2-20-01 Patient-derived triple-negative breast cancer organoids as a platform for glucocorticoid receptor- mediated mechanisms of immunotherapy response and resistance
Shiang C, Frerich C, Durdana I, Lewis C, Bennett LB, Arteaga CL, Conzen SD. UT Southwestern Medical Center; University of Texas Southwestern Medical Center; University of Texas Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA.
P2-20-02 Enrichment of atypical memory double negative (CD27— IgD—) tumour infiltrating B cells following neoadjuvant chemotherapy for early-stage breast cancer
Carpenter E, Alaguthurai T, Hossain F, Graham r, Kakkassery H, Keane S, Irshad S. King's College London; Guy's St Thomas' NHS Foundation Trust.
P2-20-03 Combination Therapy with an Anti-GD2 Antibody, Transforming Growth Factor Beta Imprinted Natural Killer Cells and Gemcitabine Improve Tumor Control and Survival in a Triple Negative Breast Cancer Model
Pereira M, Trikha P, Vasu S, Li Z, Stober DG, Lee D, Gatti-Mays M. Nationwide Childrens Hospital; OhioHealth; The Ohio State University; Pelotonia Institute for Immuno-Oncology; The Ohio State University Comprehensive Cancer Center.
P2-20-04 Vaccination against HIF1α/c-MET peptides overcome lapatinib resistance and inhibits tumor growth by immunomodulating in HER2 positive breast cancer
Lee JM, Hong JH, Lim SY, Kim JW, Lim AR, Hyun MH, Park KH. Korea University; Korea University Anam Hospital.
P2-20-05 Personalized tumor vaccine can suppress tumor growth and metastasis in the syngeneic mouse breast cancer model
Moon H-G, Son HY, Heo WH, Quan M, Li S, Valentina H, Jeong H, Han W, Lee H-B, Her Y, Kim JH. Seoul National University; Seoul National University Hospital.
P2-20-06 Anti-B7-H3 antibody (T-1A5) blocks immunomodulatory function of B7-H3 and enhances NK and T cell–mediated cytotoxicity against breast cancer cells
Anand V, Tyagi A, Battula VL. The University of Texas MD Anderson Cancer Center.
P2-20-07 Immunotherapy becomes a treatment option in cryoablated Luminal A breast cancers
Aukers Z, Klein J, Ciocca V, Zemba-Palko V, Sabol J, Ciocca R, Mandik-Nayak L, Carp N, Wallon M. Penn State College of Medicine; LMC; LIMR.
P2-20-08 Expression of ACVRL1 in a subset of recruited tumor-associated macrophages drives resistance to PD-1 therapy in human breast cancer
Safaee Talkhoncheh M, Sjölund J, Bolivar Balbas P, Kurzejamska E, Larsson S, Cordero E, Oudenaarden CR, Pantaleo J, Jonsson G, Rolny C, Bocci M, Pietras K. Lund University; Uppsala University; Karolinska institutet.
P2-20-09 Enhancement of anti-tumor immunity in ER+ breast cancer through dual inhibition of MCL1 and caspases
Yi JK, Spektor A. Dana Farber Cancer Institute.
P2-20-10 Prognostic impact of lymphocyte-Activation Gene-3 (LAG-3) expression in triple negative breast cancer
Kim J-Y, Kim J, Jung HH, Cho EY, Park YH, Ahn JS, Kim K-M, Im Y-H. Samsung Medical Center; Samsung Medical Center, Sungkyunkwan University School of Medicine / Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University.
P2-20-11 Progesterone impacts the growth and immune cell infiltration of murine mammary gland tumors
Werner LR, Helm DE, Tinoco J, Chowanec EI, Holloran SM, Hastings RC, Wei J, Lei G, Yang X-Y, Markiewicz MA, Chalise P, Balko JM, Hartman ZC, Hagan CR. University of Kansas School of Medicine; University of Kansas Medical Center; Duke Medical Center; Vanderbilt University Medical Center.
P2-20-12 Abundance of tumor-infiltrating lymphocytes is associated with pathologic complete response to neoadjuvant chemotherapy but not with survival in ER-positive/HER2-negative breast cancer
Wu R, Nagahashi M, Oshi M, Miyoshi Y, Ishikawa T, Takabe K. Roswell Park Comprehensive Cancer Center; Hyogo Medical University; Dept of Surgery, Division of Breast and Endocrine Surgery, Hyogo Medical University; Tokyo Medical University.
P2-20-13 Withdrawn
P2-20-14 Relationship of HIF-1α and tumor infiltrating lymphocytes in patients with HER2-negative early-stage breast cancer treated with neoadjuvant chemotherapy
Oza HH, Grabinski VF, Ibanez HE, Godet I, Gilkes DM, Cimino-Matthews A, Gabrielson E, Shah MY, Zhi I, Pipa Z, Lehman J, Ke S, Tsai HL, Stearns V, Santa-Maria CA. Johns Hopkins University School of Medicine; Johns Hopkins; Johns Hopkins Kimmel Cancer Center; Sidney Kimmel Cancer Center; Johns Hopkins Women's Malignancies Program; Johns Hopkins School of Medicine Division of Biostatistics; Johns Hopkins University; Memorial Sloan Kettering Cancer Center.
P2-20-15 Proteolytic regulation of CD73 by TRIM2 orchestrates tumor immunogenicity
Fu Z, Zhu Y, Kalinsky K, Wan Y. Northwestern University; Emory University; Winship Cancer Institute at Emory University, Atlanta, GA, USA.
P2-20-16 Hormone receptor expression is associated with specific immunological profiles in the breast cancer microenvironment
Hanamura T, Kitano S, Kagamu H, Yamashita M, Terao M, Okamura T, Kumaki N, Hozumi K, Iwamoto T, Honda C, Kurozumi S, Niikura N. Tokai University School of Medicine; The Cancer Institute Hospital of JFCR, Ariake, Koto-ku, Toikyo, Japan; Division of Respiratory Medicine, Saitama Medical University International Medical Center; Division of Cancer Immunotherapy Development, Center for Advanced Medical Development, The Cancer Institute Hospital of JFCR; Department of Breast Oncology, Tokai University School of Medicine; Department of Pathology, Tokai University, School of Medicine; Department of Immunology, Tokai University School of Medicine; Okayama University Hospital, Breast and Endocrine Surgery; Department of General Surgical Science, Gunma University Graduate School of Medicine; Department of Breast Surgery, International University of Health and Welfare; Tokai University School of Medicine, Isehara-shi, Japan.
P2-20-17 Eribulin is an immune potentiator in breast cancer by up-regulation of human leukocyte antigen class I
Wada A, Kutomi G, Hirohashi y, Kyuno D, Shima H, Kuga Y, Torigoe T, Takemasa I. Department of Surgery, Surgical Oncology and Science, Sapporo Medical University School of Medicine; Department of Pathology, Sapporo Medical University School of Medicine; Sapporo Medical University, Hokkaido, Japan.
   
  Tumor Cell and Molecular Biology:Microenvironment - Stromal-Epithelial Interactions
P2-21-01 Decoding inter- and intra-tumor heterogeneity in lobular breast cancer using spatial transcriptomics and clustering analysis
Serra M, Rediti M, Lifrange F, Venet D, Occelli N, Collet L, Vincent D, Rouas G, Craciun L, Larsimont D, Vikkula M, Duhoux FP, Rothé F, Sotiriou C. Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Department of Pathology, University Hospital Center of Liege, Liege, Belgium; Medical Oncology Department, Centre Léon Bérard, Lyon, France; Laboratoire d'Anatomie Pathologique, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium; Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.
P2-21-02 Longitudinal tumor-immune microenvironment changes in patients with clinical luminal A early breast cancer treated with neoadjuvant palbociclib and endocrine therapy: results from the Swedish randomized PREDIX Luminal A trial
Zerdes I, Salgkamis D, Matikas A, Selander L, Wang K, Tzoras E, Sifakis E, Agartz S, Chen X, Hellström M, Hartman J, Bergh J, Foukakis T, Hatschek T. Department of Oncology-Pathology, Karolinska, Institutet, Stockholm, Sweden; Breast Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; KIGene Core Facility, Karolinska, Institutet, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet Stockholm; Department of Oncology-Pathology, Karolinska, Institutet, Stockholm, Sweden; Centre for Clinical Cancer Trials, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska, Institutet, Stockholm, Sweden; Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden; Karolinska Institutet, Solna, Sweden.
P2-21-03 Unique collagen peptide signatures between ductal carcinoma in situ and invasive breast cancer by mass spectrometry tissue imaging
Hulahan TS, Wallace EN, Strand SH, Colditz GA, Hwang ES, West R, Spruill L, Marks J, Drake RR, Angel PM. Medical University of South Carolina; Stanford; Washington University School of Medicine; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Stanford University Medical Center; Duke University.
P2-21-04 The tumor immune microenvironment composition and prognostic value in breast cancer during pregnancy is dynamic during the gestation period
Sajjadi E, Venetis K, Ivanova M, Noale M, Blundo C, Scarfone G, Di Loreto E, Ferrero S, Maggi S, Veronesi P, Galimbreti VE, Viale G, Peccatori FAA, Guerini-Rocco E, Fusco N. European Institute of Oncology IRCCS, and University of Milan, Milan, Italy; European Institute of Oncology IRCCS, Milan, Italy; National Research Council; Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico; Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico , and University of Milan, Milan, Italy; National Research Council; Division of Breast Cancer Surgery, European Institute of Oncology, IRCCS, Milan, Italy/University of Milan, Milan, Italy; Fertility and Procreation Unit, IEO European Institute of Oncology IRCCS, Milan, Italy; Division of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy.
P2-21-05 Vascular effects of Platelet-derived growth factor-B (PDGFB) in breast cancer metastasis to the brain
Shah S, Packard R, Steck S, Mossing A, Ramamoorthy Y, Thies K, Didier A, Spehar J, Richardson D, Arsiwala T, Godbout J, Sizemore S, Lockman P, Sizemore G. The Ohio State University; West Virginia University.
P2-21-06 The relationship between the gene expression difference of fibroblasts in the tumor microenvironment and metastasis of triple-negative breast cancer
Heo WH, Lee W, Li S, Kim J-I, Moon H-G. Seoul National University.
P2-21-07 Exploring spatial correlations in Breast invasive Lobular Carcinoma subtypes using a novel CAF multiplex immunofluorescence panel
Batra H, Pandurengan RK, Ibarguen HP, McAllen SA, Ding Q, Sahin A, Wistuba I, Parra ER, Raso MG. UT MD Anderson Cancer Center; The University of Texas MD Anderson Cancer Center.
P2-21-08 Digital spatial profiling of RNA and protein in the invasive lobular breast cancer microenvironment
Bennett LB, Frerich C, Sahoo S, Lewis C, Raman I, Xu M, Chen G, Conzen SD. University of Texas Southwestern Medical Center.
P2-21-09 Detailed analyses of pro-metastatic and anti-metastatic microenvironments of murine breast tumors in syngeneic mice
Alkan F, Wilson JD, Shekastehband N, Hedrick C, Arnold A, Bollag R, Shi H, Korkaya H. Augusta University.
P2-21-10 Tumour associated macrophages in Breast Cancer - Are they critical players in response to Neo Adjuvant Chemotherapy?
Krishna L, Korlimarla A, Srinath BS, Ranjolkar A, Nascar S, Hari PS, Devi D, Nidhi I, Kumar RV. Sri Shankara Cancer Hospital and Research Center; Shankara Cancer Hospital and Research Center.
P2-21-11 A high content imaging and analysis approach to screen compounds for novel drug targets in 3D breast cancer co-culture model
Ali R, Huwaizi S, Alsubait A, Boudjelal M. KAIMRC NGHA.
P2-21-12 Targeting ADAM8 dependent maintenance of the myCAF phenotype in the breast cancer tumor microenvironment
Mi Z, Kuo PC. University of South Florida.
   
  Tumor Cell and Molecular Biology: MicroRNAs and Other Non-coding RNAs
P2-22-01 Nuclear long non-coding RNA LINC00355 expression and treatment using antisense oligonucleotides in Estrogen Receptor positive late-stage relapse breast cancer
Wells D, Gelev K, Thunugungla P, Jayasinghe R, Ding L, Shao J, Ma CX, Silva-Fisher J. Washington University in St. Louis; Washington University School of Medicine.
P2-22-02 The role of circular RNAs in triple-negative breast cancer and chemotherapy resistance
Wang X, Emch M, Hawse J. Mayo Clinic.
P2-22-03 Effect of miR-660-5p in breast cancer progression
Villarreal-García V, Estupiñan Jimenez JR, Noriega R, Bayraktar R, Reséndez-Pérez D, Rodríguez-Padilla C, Vázquez-Guillén JM, Lopez-Berestein G, Vivas-Mejía PE, Gonzalez-Villasana V. Universidad Autónoma de Nuevo León; Universidad de Puerto Rico; MD Anderson Cancer Center.
P2-22-04 Functional effect of miR-1307-3p on breast cancer progression
Estupiñan Jimenez JR, Villarreal-García V, Noriega R, Bayraktar R, Reséndez-Pérez D, Rodríguez-Padilla C, Vázquez-Guillén JM, Mar-Aguilar F, Lopez-Berestein G, Vivas-Mejía PE, Gonzalez-Villasana V. Universidad Autónoma de Nuevo León; Universidad de Puerto Rico; MD Anderson Cancer Center.
   
  Tumor Cell and Molecular Biology: Molecular Profiles
P2-23-01 Patient-derived xenografts allow deconvolution of single agent and combination chemotherapy responses in triple-negative breast cancer
Lei JT, Huang C, Srinivasan RR, vasaikar S, Dobrolecki LE, Lewis AN, Zhao N, Cao J, Hilsenbeck SG, Osborne CK, Rimawi MF, Ellis MJ, Petrosyan v, Saltzman AB, Malovannaya A, Landua JD, Wen B, Jain A, Wulf GM, Li S, Kraushaar DC, Wang T, Chen X, Echeverria GV, Anurag M, Zhang B, Lewis MT. Baylor College of Medicine; MD Anderson; Allen Institute; Zhejiang University; Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX; Harvard Medical School; Washington University School of Medicine in St. Louis; Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX, USA.
P2-23-02 Withdrawn
P2-23-03 Genomic evaluation of malignant phyllodes tumors reveals multiple targetable opportunities
Rosenberger LH, Riedel RF, Danziger NA, Sokol E, Ross JS, Sammons SL. Department of Surgery, Duke University Medical Center, Durham, NC, USA; Duke University; Foundation Medicine Inc.
P2-23-04 Moved to HER2 Session
P2-23-05 Trastuzumab-induced tumor microenvironment changes in early HER2+ breast cancer
Kennedy LC, Alvarez R, Dintzis S, Gadi VK. Vanderbilt University Medical Center; University of Washington; University of Illinois.
P2-23-06 Estrogen receptor-negative progesterone receptor-positive breast cancer is a molecularly distinct group characterized by the down-regulation of genes controlled by ESR1 and SUZ12
Kunc M, Popęda M, Bieńkowski M, Braun M, Łacko A, Radecka B, Pikiel J, Litwiniuk M, Pogoda K, Niemira M, Szałkowska A, Iżycka-Świeszewska E, Cserni G, Biernat W, Senkus E. Department of Pathomorphology, Medical University of Gdańsk, Poland; Department of Pathology, Chair of Oncology, Medical University of Łódź; Department of Oncology, Wrocław Medical University; Oncology Department with Daily Unit, Tadeusz Koszarowski Cancer Center in Opole, Opole, Poland; Regional Oncology Center, Department of Oncology, Gdynia, Poland; Greater Poland Cancer Centre, Poznan; University of Medical Sciences, Poznan, Poland; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Clinical Research Centre, Medical University of Bialystok; Department of Pathology and Neuropathology, Medical University of Gdańsk; Institute of Pathology, University of Szeged, Szeged, Hungary; Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; Department of Oncology.and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
P2-23-07 DNA methylation analysis of triple negative breast cancers
Lin LH, Tran I, Yang Y, Cotzia P, Roses D, Schnabel F, Darvishian F, Snuderl M. NYU Grossman School of Medicine; NYU.
P2-23-08 Concordance of targeted sequencing from circulating tumor DNA and paired tumor tissue
Huang C-C, Tseng L-M. Taipei Veterans General Hospital.
P2-23-09 Ultra-high tumor mutation burden in metastatic/clinically advanced breast cancer (MBC)
Fanucci K, Lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Ashok Kumar P, Kallem M, Danziger NA, Sokol E, Sivakumar S, Pavlick D, Ross JS, Pusztai L. Yale Cancer Center; Yale University; Foundation Medicine Inc.; Upstate Medical University; SUNY Upstate Medical University; Upstate Medical University; Yale University Cancer Center, New Haven, CT, USA.
P2-23-10 Gene expression and mutation profiles in HER2-mutated metastatic breast cancer
Hensin WL, Thomas SN, El-Refai S, Mauer E, Ma CX, Bose R. St. Luke's Cancer Institute, UMKC School of Medicine; Washington University in St. Louis School of Medicine; Tempus Labs, Inc.; Washington University School of Medicine.
P2-23-11 Quantitative gene expression by RT-PCR in histologic subtypes of invasive breast carcinoma: an update in nearly one million cases
Can NT, Flannery CA, Hoag J, Akkunuri A, Bailey H, Baehner F. Exact Sciences.
P2-23-12 The mutational landscape of 1172 patients with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors
Shah AN, Lim B, Mita MM, Mauer E, Layng KV, Chao C, Brufsky AM. Northwestern University; Dan L. Duncan Comprehensive Cancer Center Baylor College of Medicine Houston, TX; Cedars-Sinai; Tempus Labs, Inc.; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center.
P2-23-13 Highly proliferative estrogen receptor-positive breast cancer is associated with better response to neoadjuvant chemotherapy but worse clinical outcome
Wu R, Tokumaru Y, Asaoka M, Oshi M, Yan L, Ishikawa T, Takabe K. Roswell Park Comprehensive Cancer Center; Breast Surgery, Gifu University Hospital; Tokyo Medical University.
P2-23-14 Molecular characterization of HER2-low invasive breast carcinoma by quantitative RT-PCR using Oncotype DX®
Rozenblit M, Lin H-K, Can NT, Flannery CA, Hoag J, Akkunuri A, Bailey H, Baehner F, Pusztai L. Yale Cancer Center; Yale Cancer Center, Yale School of Medicine; Exact Sciences; Yale University Cancer Center, New Haven, CT, USA.
P2-23-15 Histologic, immunohistochemical and genomic comparison between classic Invasive lobular carcinomas and lobular-like invasive ductal carcinomas
da Silva EM, Basili T, Yu J, Blanco-Heredia J, Selenica P, Ye Q, da Cruz Paula A, Dopeso H, Marra A, Oesterreich S, Reis-Filho J, Bhargava R. Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pathology, Magee-Womens Hospital of UPMC; Memorial Sloan Kettering Cancer Center; University of Pittsburgh; Memorial Sloan Kettering Cancer Center, New York, NY, USA; UPMC Magee-Womens Hospital.
P2-23-16 Clinico-pathological and molecular characterization of HER2-enriched breast tumors independently of HER2 status
Muñoz-Carrillo FJ, Paré L, Conte B, Rodríguez A, Galván P, Sanfeliu E, González-Farré B, Falato C, Garcia-Fructuoso I, Adamo B, Chic N, Martínez-Sáez O, Pascual T, Moreno R, Muñoz M, Brasó-Maristany F, Prat A, Schettini F, Vidal M. Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; SOLTI Breast Cancer Research Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Faculty of Medicine and Pathology Department, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain; Pathology Department, Hospital Clínic of Barcelona, Barcelona, Spain ; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain ; SOLTI cooperative group, Barcelona ; Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain; Medical Oncology Department, Hospital Clínic de Barcelona ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; Hospital Clínic of Barcelona, Barcelona, Spain ; August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain ; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain ; SOLTI Breast Cancer Research Group, Barcelona, Spain; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain; SOLTI Breast Cancer Research Group, Hospital Clínic of Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain ; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS); Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Breast Cancer Unit, IOB-Quirón Salud, Barcelona, Spain; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain ; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Medical Oncology Department, Hospital Clínic of Barcelona ; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain ; SOLTI Breast Cancer Research Group ; Faculty of Medicine and Health Sciences, University of Barcelona.
P2-23-17 Programmed death ligand-1 expression in triple-negative breast cancer from Nigeria
Olasehinde O, Wuraola F, Kajetanowicz A, Bethune G, Edelweiss M, Ntiamoah P, Odujoko O, Sharma A, Mango V, Kingham P, Alatise O, Knapp G. Obafemi Awolowo University; Dalhousie University; Memorial Sloan Kettering Cancer Center; Danbury Hospital; University of Auckland.
P2-23-18 Analysis of serum galectin profiles by breast cancer subtypes and patient characteristics
Shealy J, Kesic A, Funkhouser A, Martin J, Gluck WL, Edenfield WJ, Blenda A. University of South Carolina School of Medicine Greenville; Prisma Health
P2-23-19 Interrogating multicellular signaling in breast cancer using a bio-orthogonal chemistry-based proteomics platform
Krajina BA, Yamamoto A, Cheung KJ, Madasu S. Fred Hutchinson Cancer Center.
   
  Tumor Cell and Molecular Biology: New Drugs and Mechanisms
P2-24-01 The development of covalent microtubule stabilizers for drug-resistant cancers
Essif JN, Risinger A. UT Health San Antonio.
P2-24-02 Analyzing susceptibility to macrophage-activating immunotherapy bexmarilimab in breast cancer by using patient-derived tumor explants
Rannikko JH, Virtakoivu R, Takeda A, Boström P, Koskivuo I, Bono P, Hollmén M. MediCity Research Laboratory, University of Turku, Finland; Orion Corporation, Finland; Department of Pathology, Turku University Hospital, Finland; Department of Plastic and General Surgery, Turku University Hospital, Finland; Terveystalo Finland, Helsinki, Finland; MediCity Research Laboratory, University of Turku, Finland.
P2-24-03 Z-endoxifen allosterically inhibits PKCβI and its paradoxical membrane translocation
Sarkar Bhattacharya S, Witter TL, Cong AT, Bruinsma ES, Jayaraman S, Goetz MP, Hawse J, Schellenberg M. Mayo Clinic; Mayo Foundation; Mayo Clinic, Rochester, MN
P2-24-04 The ER antagonist giredestrant induces profound chromatin remodeling including activation of cis-regulatory elements bound by FOXA1 and GATA3 in HR+ breast cancer models
Ahmed M, Guan J, Zhou W, Yao X, Metcalfe C, Hafner M. Roche Canada; Genentech, Inc.
P2-24-05 TAVO412 - A novel trispecific cMet x EGFR x VEGF antibody for triple negative breast cancer
Chiu M. Tavotek Biotherapeutics.
P2-24-06 αEGFR-E-P125A antibody-endostatin fusion protein reduces vasculogenic mimicry and tumor cell motility by inhibition of EGFR, integrin and FAK signaling
Sankar AP, Gil Henn H, Cho HM, Nassar D, Ramakrishnan S, Das R, Zhang Y, Elledge C, Shin S-U, Rosenblatt J. University of Miami Miller School of Medicine; Bar Ilan University, Azrieli Faculty of Medicine; Synergys Biotherapeutics.
P2-24-07 Combination of complete estrogen receptor antagonist, OP-1250, and CDK4/6 inhibitors enhances tumor suppression and inhibition of cell cycle-related gene expression
Parisian AD, Palanisamy GS, Ortega F, Sapugay JL, Bodell WJ, Kulp D, Kushner P, Harmon C. Olema Oncology.
P2-24-08 Altersolanol B, a fungal metabolite, induces proteasome-dependent degradation of estrogen receptor α (ERα) and inhibits downstream signaling targets in ER+ breast adenocarcinoma cells
Siraj MA, Rahman MS, Jacobs AT, Tan GT. University of Hawaii at Hilo; South Dakota State University; California University of Science and Medicine.
   
  Tumor Cell and Molecular Biology: Oncogenes/Tumor Suppressor Genes
P2-25-01 TRPS1 regulates angiogenesis via JAG1 and TYMP in triple-negative breast cancer
Guzman L, Ayerbe C, Rangel R, Chang J, Rosato R. Houston Methodist; Houston Methodist Research institute; MD Anderson Cancer Center; Houston Methodist Hospital.
P2-25-02 Withdrawn
P2-25-03 β-arrestin1, a potential tumour suppressor in breast cancer is downregulated in PERK/ATF4-dependent manner
Sultana A, Gupta A, Gupta S. National University of Ireland, Galway (NUIG).
P2-25-04 Granzyme B expression in tumor microenvironment as a biomarker for prognosis of triple-negative breast cancer
Mizoguchi K, Nakamura M. Dept. Surgery and Oncology, Kyushu Universty.
   
  Tumor Cell and Molecular Biology: Other
P2-26-01 Prospective breast biopsy collection at an urban safety-net hospital serving a diverse patient population
Ilinski A, Mahdaviani K, Fishman M, Cassidy M, Ko N. Boston Medical Center; Boston University School of Medicine.
P2-26-02 Valproic acid induces apoptosis and mitochondrial perturbations in breast cancer cells
Paolì A, Forestiero M, Naimo GD, Mauro L, Panno ML, Giordano F. Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Cosenza, Italy.
P2-26-03 TRAF3 as a regulator of breast cancer aggressiveness
Papanastasiou A, Sirinian C, Theakou M, Peroukidis S, Chaniotis D, Kalofonos H, Koutras A. University of West Attica; University of Patras; Panarkadikon General Hospital.
P2-26-04 Human papillomavirus protein E6 regulates Toll like receptor-9 expression in breast cancer cells
Parviainen E, Nurmenniemi S, Bravaccini S, Pirini F, Ravaioli S, Jukkola A, Selander KS. Oulu University Hospital; University of Oulu; IRCCS Istituto Romagnolo Per lo Studio dei Tumori, Meldola, Italy; Tampere University Hospital; Oulu University Hospital.
P2-26-05 Withdrawn
P2-26-06 Association between CK+/CD45+ circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) alterations in advanced breast cancer patients
Reduzzi C, Gerratana L, Zhang Y, Manai M, D'Amico P, Davis AA, Donahue J, Shah AN, Cristofanilli M. Weill Cornell Medicine; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano; Northwestern Medicine Northwestern University; Northwestern University; Washington University in St Louis School of Medicine; Weill-Cornell; Northwestern University - Feinberg School of Medicine.
P2-26-07 Alteration of gut microbiota signatures and its association with diarrhea during abemaciclib treatment: A multicenter prospective cohort study (KBCRN-A002 study)
Kawaguchi K, Maeshima Y, Ishiguro H, Yamagami K, Takahara S, Suwa H, Torii M, Nagai S, Sagara Y, Tsuji W, Yamashiro H, Kotake T, Fukuda S, Saito K, Yamamoto Y, Kataoka M, Himoto Y, Yonezawa A, Fukui Y, Nakamura Y, Li W, Tanaka S, Morita S, Toi M. Department of Breast surgery, Kyoto University Hospital; Department of Breast Surgery, Kyoto University Hospital, Graduate School of Medicine; Saitama Medical University International Medical Center; Shinko Hospital; Tazuke Kofukai, Medical Research Institute, Kitano Hospital; Hyogo Prefectural Amagasaki General Medical Center; Japanese Red Cross Wakayama Medical Center; Saitama Prefectural Cancer Center; Hakuaikai Sagara Hospital; Shiga general Hospital; Tenri Hospital; Kansai Electric Power Hospital; Keio University; Fujita Health University; Kyoto University Hospital; Department of Breast Surgery, Kyoto University Hospital, Graduate School of Medicine; Department of Breast Surgery, Kyoto University Graduate School of Medicine.
P2-26-08 Influence of genetic ancestry on breast stromal cells provides biologic basis for increased incidence of metaplastic breast cancer in women of African descent
Kumar B, Batic K, Bhat-Nakshatri P, Granatir M, Addison R, Szymanski M, Baldridge LA, Temm C, Sandusky G, Althouse S, Storniolo AM, Nakshatri H. Indiana University School of Medicine; Indiana University.
P2-26-09 Synergistic activity of PI3K inhibitor in combination with AZD6738, ATR inhibitor in breast cancer preclinical model via DNA damage response pathway
Moon YW, Gosh M, Park N, Pandey K, Katwal NB, Hong SD. CHA Bundang Medical Center; The Graduate School, CHA University.
P2-26-10 Statins exhibit an anti-tumor effect by attenuating PD-L1 in breast cancer cells and macrophages and reducing breast tumor progression in xenograft mouse model
Lee S, Kim HS, Yoon S-H, Ryu S, Baek M, Park AY, Lee H-B, Han W. Seoul National University; Seoul National University Hospital.
P2-26-11 Protein phosphatase 1 catalytic units, PPP1CA, PPP1CB and PPP1CC in breast cancer
Dong X, Martin TA, Dou Q, Jiang WG, Davies E. Cardiff University; Wayne State University School of Medicine.
P2-26-12 Interaction between CTCs and platelets complicate their detection by masking surface epitopes
Schott D, Pizon M, Pachmann K. Transfusion Center Bayreuth.
P2-26-13 Gene deletion of insulin receptor in MCF-7L breast cancer cells by CRISPR gene editing
Zhang X, Monteiro M, Yee D. University of Minnesota; Masonic Cancer Center, University of Minnesota.
P2-26-14 CDK4/6 inhibitors modulate the ubiquitin–proteasome pathway in ER+ breast cancer by downregulation of UBE2C/S/T
Lin C-Y, Yu C-J, Liu C-Y, Chao T-C, Huang C-C, Tseng L-M, Lai J-I. National Yang-Ming Chiao-Tung University; Department of Transfusion Medicine, Taipei Veterans General Hospital; Department of Oncology, Taipei Veterans General Hospital; Department of Surgery, Taipei Veterans General Hospital.
P2-26-15 CCR7 expression in Inflammatory breast cancer
Balema W, Krishnamurthy S, Lawrence A, Rodriguez M, Larson R, Fowlkes n, Ueno NT, Woodward WA. University of Texas MD Anderson Cancer Center; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P2-26-16 Withdrawn
P2-26-17 Establishment of an in vitro preclinical platform: A living biobank of patient-derived organoids with ER+ breast cancer
Dominguez-Cejudo MA, Chapresto R, Gil-Torralvo A, Salvador Bofill FJ, Molina-Pinelo S. Instituto de Biomedicina de Sevilla IBiS. Hospital Universitario Virgen del Rocío / CSIC / US, Molecular and translational research in oncology, Seville, Spain; Hospital Universitario Virgen del Rocío, Seville, Spain.
P2-26-18 Adiponectin regulates stem cell activity in tamoxifen-resistant breast cancer cells
Naimo GD, Forestiero M, Paolì A, Giordano F, Panno ML, Mauro L, Andò S. Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Cosenza, Italy.
P2-26-19 Slc26a9 cooperates with HER2 to regulate the progression and development of HER2-positive breast cancer
Zhou Z, Ma Z, Liu X, Zhang C, Wang H, Mu R, Cheng X, Tuo B, Li T. Breast and Thyroid Surgery, Department of General Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, China; Afliated Hospital of Zunyi Medical University.
P2-26-20 Marvel D3 and its associated junctional proteins in breast cancer
Ji W, Jiang WG, Martin TA. Cardiff University.
P2-26-21 The principal factors associated with engraftment success of patient-derived xenograft of breast cancer
Lee J, Lee U, Lee HJ, Gong G. Asan Medical Center; NeogenTC Corp.; University of Ulsan College of Medicine, Asan Medical Center.
P2-26-22 Elevated expression of high mannose glycans in tissue and serum samples of breast cancer patients
Kesic A, Funkhouser A, Shealy J, Martin J, Gluck WL, Edenfield WJ, Blenda A. University of South Carolina School of Medicine Greenville; Prisma Health.
P2-26-23
Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple negative breast cancer (TNBC)

Desmoulins I, Chardin D, Richard C, Arnould L, Cochet A, Humbert O, Boidot R